
==== Front
Mol Cancer
Mol Cancer
Molecular Cancer
1476-4598
BioMed Central London

2106
10.1186/s12943-024-02106-8
Review
Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications
Lin Zhengjun 12
Li Guoqing 12
Jiang Ke 13
Li Zhihong lizhihong@csu.edu.cn

1
Liu Tang liutang1204@csu.edu.cn

1
1 grid.216417.7 0000 0001 0379 7164 Department of Orthopedics, The Second Xiangya Hospital, Central South University, 139# Middle Renmin Road, Changsha, Hunan Province 410011 China
2 https://ror.org/00f1zfq44 grid.216417.7 0000 0001 0379 7164 Xiangya School of Medicine, Central South University, Changsha, 410013 Hunan Province China
3 https://ror.org/00f1zfq44 grid.216417.7 0000 0001 0379 7164 Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410078 China
7 9 2024
7 9 2024
2024
23 19131 7 2024
2 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Cancer-associated fibroblasts (CAFs) are a diverse stromal cell population within the tumour microenvironment, where they play fundamental roles in cancer progression and patient prognosis. Multiple lines of evidence have identified that CAFs are critically involved in shaping the structure and function of the tumour microenvironment with numerous functions in regulating tumour behaviours, such as metastasis, invasion, and epithelial-mesenchymal transition (EMT). CAFs can interact extensively with cancer cells by producing extracellular vesicles (EVs), multiple secreted factors, and metabolites. Notably, CAF-derived EVs have been identified as critical mediators of cancer therapy resistance, and constitute novel therapy targets and biomarkers in cancer management. This review aimed to summarize the biological roles and detailed molecular mechanisms of CAF-derived EVs in mediating cancer resistance to chemotherapy, targeted therapy agents, radiotherapy, and immunotherapy. We also discussed the therapeutic potential of CAF-derived EVs as novel targets and clinical biomarkers in cancer clinical management, thereby providing a novel therapeutic strategy for enhancing cancer therapy efficacy and improving patient prognosis.

Keywords

Cancer-associated fibroblasts
Extracellular vesicles
Therapy resistance
Clinical biomarker
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82072441 http://dx.doi.org/10.13039/501100020795 Outstanding Youth Scientist Foundation of Hunan Province 2022JJ10095 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Cancer continues to be a serious public health challenge affecting people worldwide [1, 2]. Despite the substantial investment in cancer research and the extensive array of anti-cancer treatments available, therapy resistance remains the most serious factor impeding therapeutic efficacy [3, 4]. The intricate panorama of cancer therapy resistance entails multifaceted mechanisms such as altered drug uptake and efflux, inhibition of apoptosis signaling pathways, activation of cancer stem cells (CSCs), enhanced DNA repair capacities, disrupted cell cycle regulation, and physical obstacles impairing drug penetration and efficacy [5–7]. Nowadays, multiple ongoing studies have explored new drugs and combinations to address therapy resistance. For instance, bufalin, a compound found in secretions from the glands of toads can effectively inhibit cancer progression and reverse various drug resistance mechanisms, supporting combining bufalin with standard therapies as a promising therapeutic strategy [8–11]. However, the complex molecular mechanisms behind cancer therapy resistance remain largely elusive. Notably, complex biological interactions between the tumour and tumour microenvironment have been confirmed as an essential factor that leads to cancer treatment failure. Multiple non-tumour cell types within tumour microenvironment interact closely with tumour cells and either positively or negatively mediate cancer therapy resistance [12, 13].

Cancer-associated fibroblasts (CAFs) are a major component of the stroma and are critically involved in the maintenance and reshaping of the extracellular matrix (ECM) [14, 15]. CAFs may originate from multiple cellular types, including quiescent tissue-resident fibroblasts, pancreatic or hepatic stellate cells, bone marrow-derived mesenchymal stem cells, endothelial cells, pericytes, and adipocytes [14, 16]. Multiple mechanisms have been confirmed to induce CAFs activation, including cancer cell-CAFs interacting signaling, ECM remodeling, oxidative stress, signals from other cells within the tumour microenvironment, cancer therapies, numerous tumor-inhibiting/promoting functions. Mechanistically, CAFs can regulate multiple tumour behaviours by secreting various cytokines, exosomes, and metabolites or by remodeling the structure and functions of the surrounding ECM [17, 18]. For instance, CAFs can produce TGFβ, fibroblast growth factor 5 (FGF5), and hepatocyte growth factor (HGF) to facilitate the invasion, proliferation, and therapy resistance of cancer cells [19]. On the contrary, CAFs can exert tumour-inhibiting functions by enhancing anticancer immunity, secreting pro-inflammatory cytokines, and producing certain ECM components as barriers to inhibit tumour cell invasion and dissemination [18] (Fig. 1).Fig. 1 Overview of CAFs. Potential cellular origins of CAFs include quiescent stellate cells, tissue-resident fibroblasts, mesenchymal stem cells (MSCs), endothelial cells, pericytes, and other cell types. CAFs can be activated by various mechanisms, including ECM remodeling, inflammation, oxidative stress and signalling interaction with cancer cells or other cells within tumour microenvironment. Activated CAFs can exert either tumour-restraining or tumour-promoting functions by secreting cytokines, exosomes, remodeling ECM and altering metabolism

Extracellular vesicles (EVs) are heterogeneous cell-derived membrane structures composed of exosomes and microvesicles that originate from the endosomal system or are shed from the plasma membrane, respectively [20, 21]. EVs harbor a rich cargo of molecules, including nucleic acids like DNA, mRNAs, and noncoding RNAs (ncRNAs), as well as lipids and diverse proteins. Functionally, EVs serve as vital mediators of intercellular communication, shuttling a plethora of molecules that regulate cellular processes in both normal and pathological contexts [22, 23]. Notably, multiple studies have highlighted the pivotal role of CAF-derived EVs in shaping the tumor microenvironment and influencing the development of various human cancers [24, 25]. For instance, CAF-derived EV-packaged PIAT can promote neural remodeling by enhancing the binding of YBX1 and PNI-associated mRNAs in a m5C-dependent manner in pancreatic cancer [26]. Intriguingly, CAF-derived EVs are implicated in mediating resistance to cancer therapies, including chemotherapy, targeted therapy, radiotherapy, and immunotherapy, indicating that CAFs and CAF-derived EVs can constitute a novel therapeutic target.

This review explores the crucial roles played by CAF-derived EVs in mediating resistance to cancer therapies and delves into the intricate mechanisms through which CAF-derived EVs bolster or undermine anticancer therapy resistance. Additionally, we discussed the prognostic value and therapeutic potential of CAF-derived EVs in cancer management.

CAF-derived EVs in cancer therapy resistance

Therapeutic resistance is a significant obstacle in enhancing cancer therapy efficacy and improving patient prognosis. Although multiple studies have proposed a conceptual framework of therapy resistance mechanisms, and novel therapeutic agents and combinational therapies have been developed to conquer the development of acquired therapy resistance, the complex biological mechanisms underlying cancer therapy resistance remain largely elusive. Hence, elucidating the detailed mechanisms of cancer therapy resistance and identifying novel therapy resistance-related biomarkers are critical for advancing personalized precision medicine and improving patient prognosis. Notably, ectopic alterations in CAFs and CAF-derived EVs have been found in the tumour microenvironment in various therapy-resistant cancers, indicating the role of CAF-derived EVs in cancer therapy resistance. The involvement of CAF-derived EVs in cancer resistance to chemotherapy, targeted therapy, radiotherapy and immunotherapy is summarized below (Table 1). Table 1 CAF-derived EVs in cancer chemotherapy resistance

Key cargo	Cancer type	Genes and pathways or biological processes	Drug	Chemical structure	Drug resistance	Ref	
miR-106b	PDAC	TP53INP1	GEM		↑	[29]	
miR-130a	NSCLC	PUM2	DDP		↑	[32]	
miR-20a	NSCLC	PTEN and PI3K/AKT	DDP		↑	[33]	
miR-522	GC	ALOX15 and USP7/hnRNPA1	DDP and PTX		↑	[42]	
miR-3173-5p	PDAC	ACSL4	GEM		↑	[43]	
miR-432-5p	PC	CHAC1	DTX		↑	[44]	
-	ESCC	RIG-I/IFN-β	DDP		↑	[46]	
miR-146a	PDAC	Snail	GEM		↑	[50]	
miR-148b-3p	BCa	PTEN and the Wnt/β-catenin	PTX and DOX		↑	[51]	
miR-92a-3p	CRC	Wnt/β-catenin	5-FU/

OXA

		↑	[52]	
miR-21	PC	RAS/ATK/ERK axis	GEM		↑	[54]	
miR-4717-5p	ML	ENT2	anti-pyrimidine		↑	[57]	
miR-146a-5p	UBC	ARID1A and PRKAA2	GEM and DDP		↑	[59]	
miR-423-5p	PC	GREM2 and TGF-β	Taxane		↑	[37]	
miR-296-3p	OC	PTEN/AKT and SOCS6/STAT3	PTX		↑	[38]	
miR-21	OC	APAF1	PTX		↑	[39]	
miR-21	ESCC	STAT3	DDP		↑	[34]	
miR-24-3p	CC	CDX2/HEPN	MTX		↑	[35]	
miR-34c-5p	LSCC		DDP		↑	[60]	
LINC00355	BCa	miR-34b-5p/ABCB1	DDP		↑	[62]	
LncRNA UCAI	VSCC	miR-103a-WWE1 axis	DDP		↑	[64]	
LncMEG3	SCLC	miR-15a-5p/CCNE1 axis	DDP		↑	[65]	
LncFAL1	CRC	TRIM3 and Beclin1	OXA		↑	[66]	
LncCCAL	CRC	HuR/β-catenin	OXA		↑	[67]	
DACT3-AS1	GC	miR-181a-5p/

SIRT1

	OXA		↑	[68]	
circZFR	HCC	STAT3/NF-κB	DDP		↑	[70]	
CircN4BP2L2	CRC	PI3K/AKT/mTOR axis	OXA		↑	[71]	
circFARP1	PDAC	LIF/STAT3 axis	GEM		↑	[72]	
circBIRC6	PDAC	XRCC4	OXA		↑	[73]	
FOSL1	CRC	ITGB4	OXA		↑	[74]	
VEGFA	CRC		DDP		↑	[76]	

CAF-derived EVs in cancer chemotherapy resistance

As the first-line mode of anti-tumour treatment in multiple malignancies, multiple chemotherapeutic drugs with different properties and targets have exhibited prominent effectiveness. Nonetheless, both the inherent and acquired chemotherapy resistance take primary responsibility for treatment failure, adverse prognosis, and high recurrence rate. Multiple studies have demonstrated that CAF-derived EVs consisting of functional non-coding RNAs and proteins are critically involved in mediating cancer chemotherapy resistance through complex mechanisms and signaling pathways [27–30] (Fig. 2).Fig. 2 CAF-derived EVs in cancer chemotherapy resistance. The detailed biological mechanisms of CAF-derived EVs in mediating cancer chemoresistance are summarized. CAF-derived EVs can deliver miRNAs, lncRNAs, circRNAs and proteins to mediate cancer chemotherapy resistance by regulating cell cycle, DNA repair, oxidative stress, EMT, apoptosis, autophagy, cancer cell stemness, angiogenesis, immune cells infiltration and various signalling pathways including PI3K/AKT, Wnt/β-catenin, and PTEN/mTOR pathways

miRNAs

MicroRNAs (miRNAs) are about 21–23 nucleotides in length and function by binding to the 3’ untranslated region of target mRNA, leading to mRNA degradation or translational repression [31]. CAFs can deliver diverse miRNAs to targeted cancer cells through EVs, thus regulating cancer therapy resistance. For instance, CAF-derived exosomal miR-130a has been confirmed to promote cisplatin (DDP) resistance in NSCLC, and the packing and secretion of exosomal miR-130a were regulated by the PUM2 in CAFs [32]. Similarly, miR-20a was abnormally upregulated in NSCLC patient tissue samples and CAF-derived exosomes from NSCLC patients compared with normal tissues and NAFs from healthy paracancerous lung tissues, respectively. Functionally, CAF-derived exosomal miR-20a can promote tumour progression and DDP resistance by inhibiting PTEN and activating PI3K/AKT pathway in vivo and in vitro [33]. Monocytic myeloid-derived suppressor cells (M-MDSCs) have been found to correlate with DDP resistance in patients with ESCC, and CAFs can facilitate the differentiation of monocytes into M-MDSCs phenotypically and functionally in vitro. Mechanically, CAFs secreted IL-6 and exosomal miR-21 to promote M-MDSCs formation by stimulating the STAT3 signaling pathway, and CAFs-induced M-MDSCs promoted DDP resistance of ESCC cells [34]. In colon cancer, miR-24-3p transferred from CAFs to cancer cells through exosomes downregulated the expression of CDX2 and HEPN, inducing the methotrexate (MTX) resistance in both in vivo and in vitro experiments [35]. Taxanes are the first-line anti-tumor drugs for many malignant tumors via inhibiting microtubules, inducing inflammatory response and apoptosis, etc [36]. Both in vivo and in vitro experiments have revealed that CAF-derived exosomal miR-423-5p targeted 3’-UTR of GREM2 to stimulate the TGF-β signaling pathway, thereby resulting in the therapy resistance to taxane in prostate cancer [37]. Sun et.al have reported that miR-296-3p, which was upregulated in activated CAFs‐derived EVs from ovarian cancer, can promote ovarian cancer progression and paclitaxel resistance by regulating PTEN/AKT and SOCS6/STAT3 signaling pathways [38]. CAFs‐derived exosomal miR-21 can also induce ovarian cancer paclitaxel resistance, migration, and invasion by directly targeting apoptosis protease activating fator1(APAF1) [39].

Ferroptosis is a novel form of regulated cell death that involves iron-dependent lipid-ROS accumulation [40]. Ferroptosis has been identified as an important regulator of cancer therapy resistance, and inducing ferroptosis is a novel therapeutic strategy to reverse drug resistance [41]. Zhang et al. have isolated serum exosomes from gastric cancer patients and normal controls by ultra-centrifugation, and found that the expression level of miR-552 was abnormally elevated in both tumour tissues and serum exosomes of gastric cancer patients. Further investigation has reported that DDP and paclitaxel treatment can induce CAFs to secret exosomal miR-552 by activating the USP7/hnRNPA1 axis in gastric cancer. Meanwhile, CAF-derived exosomal miR-552 can impair chemosensitivity by inhibiting ferroptosis by suppressing ALOX15 [42]. Similarly, Qi et al. have obtained normal fibroblasts and CAFs from normal paracancerous pancreatic tissues and PDAC tumors respectively, and isolated normal fibroblast- and CAF-derived exosomes by ultracentrifugation. CAF-derived exosomes can inhibit ferroptosis in pancreatic cancer cells after gemcitabine (GEM) treatment in a non-contact co-culture system in vitro. Besides, miR-3173-5p was upregulated in co-induced CAF-derived exosomes and tumor tissues after GEM treatment. The mechanical investigation suggested that CAF-derived exosomal miR-3173-5p facilitated GEM resistance and suppressed ferroptosis by directly targeting ACSL4 in vivo and in vitro [43]. In prostate cancer, CAF-derived exosomal miR-432-5p reduces lipid peroxidation stress and inhibits ferroptosis by targeting CHAC1, thereby conferring docetaxel (DTX) resistance [44].

Evasion of apoptosis has been regarded as a major cause of cancer chemoresistance [45]. In esophageal squamous cell carcinoma (ESCC), CAF-derived exosomes decreased the chemotherapy sensitivity of DDP and inhibited ESCC cell apoptosis via the RIG-I/IFN-β signaling in vivo and in vitro [46]. Pancreatic fibroblasts have exhibited innately chemoresistant to GEM, and co-culturing PDAC cells with CAFs improved PDAC proliferation capability and reduced GEM-induced cell apoptosis by establishing a three-dimensional organoid-fibroblast co-culture system [47]. Simultaneously, miR-106b was upregulated in GEM-treated CAFs and CAF-derived exosomes, and exosomal miR-106b possessed the potential to promote acquired resistance to GEM via binding to Tumor protein p53-inducible nuclear protein 1 (TP53INP1) [29]. Korc et al. have isolated GEM-treated CAF-derived exosomes by ExoQuick-TC™ and microRNA-Seq was conducted to select differentially expressed miRNAs. The abnormal upregulation of a total of five miRNAs (miR-21, miR-181a, miR-221, miR-222, and miR-92a) was detected in GEM-treated CAF-derived exosomes, and these exosomal miRNAs may confer GEM resistance by directly targeting PTEN [48].

Epithelial-mesenchymal transition (EMT) plays multifaceted roles in cancer progression, metastasis, and therapy resistance, and targeting the EMT process and EMT transcription factors, e.g. ZEB, TWIST and SNAIL has become promising approaches to reverse therapy resistance [49]. GEM treatment can induce CAFs to secret more miR-146a and the specific promoter binding transcription factor of miR-146a, Snail, subsequently inducing EMT and chemoresistance to GEM in vitro [50]. CAF-derived exosomal miR-148b-3p has been demonstrated to induce the chemoresistance to PTX and DOX through inducing EMT by directly targeting PTEN and the Wnt/β-catenin pathway in bladder cancer, whereas the downregulation of miR-148b-3p and expression of PTEN could reverse the chemoresistance via the Wnt/β-catenin pathway [51]. 5-FU/L-OHP has a prominent chemotherapy effect on colorectal cancer (CRC). Hu et al. have isolated normal fibroblast- and CAF-derived exosomes by ultracentrifugation, and found that CAF-derived exosomes can facilitate invasion, metastasis, and chemotherapy resistance in CRC. miRNA microarray assay revealed that miR-92a-3p was significantly upregulated in CAFs and CAF-derived exosomes, and exosomal miR-92a-3p secreted by CAFs has been found to promote EMT, cell stemness, 5-FU/L-OHP resistance, and suppress mitochondrial apoptosis of CRC cells in vivo and in vitro. Mechanically, exosomal miR-92a-3p directly activated the Wnt/β-catenin signaling pathway and inhibited the expression of FBXW7 and MOAP [52].

Oxidative stress is an adverse condition for cancer cells survival, whereas the hypoxic microenvironment is one of the key factors that promote cancer progression and facilitate therapy resistance [53]. In pancreatic cancer, hypoxia-induced CAFs can secret miR-21 abundant extracellular vesicles to promote pancreatic cancer cell stemness and GEM resistance [54]. Mechanically, the hypoxic microenvironment induced miR-21 secretion through HIF-1α activation, and miR-21 conferred resistance to GEM by activating the RAS/ATK/ERK axis [54]. Aerobic glycolysis is a typical phenotype of cancer cells, and glycolysis is also a determinant of cancer chemoresistance [55, 56]. In malignant lymphoma, CAF-derived exosomes can support the survival of lymphoma cells by promoting glycolysis, and inhibition of exosome secretion by RAB27B suppression inhibits the survival of lymphoma cells. Besides, CAF-derived exosomal miR-4717-5p can induce anti-pyrimidine drug resistance by directly targeting ENT2 in lymphoma [57]. Cancer stem cells have been identified as a critical factor for tumor growth, chemoresistance, and recurrence, and tackling stemness-associated chemoresistance may be an effective therapy approach [58]. In urothelial bladder cancer (UBC), CAF-derived exosomal miR-146a-5p can facilitate cancer stem cell niche formation, UBC cell stemness, and resistance to GEM and DDP by directly targeting the 3’UTR of mRNAs of ARID1A and PRKAA2. Mechanically, the downregulation of ARID1A can suppress the expression of SOCS1 and activate the STAT3 signaling pathway, and downregulated PRKAA2 can activate the mTOR signaling [59]. In vivo study has demonstrated that CAF-derived exosomal miR-34c-5p reduced the DDP resistance and stemness of laryngeal squamous cell carcinoma (LSCC) [60].

LncRNAs

LncRNAs are ncRNAs that are longer than 200 nt without protein-coding potential [61]. Multiple studies have indicated that CAF-derived exosomal lncRNAs can interact with multiple miRNAs in cancer cells to mediate chemoresistance. For instance, exosomal LINC00355 secreted by CAFs promoted DDP resistance by sponging miR-34b-5p to upregulate ABCB1 in bladder cancer [62]. Intriguingly, the LINC00355/miR-34b-5p axis was also involved in facilitating EMT and the chemoresistance to DDP, OXA, and 5-FU in CRC [63]. Correspondingly in vulvar squamous cell carcinoma (VSCC) cells, exosomal lncRNA UCAI from CAFs can induce DDP resistance via the miR-103a-WWE1 axis [64]. Exosomal lncMEG3 was secreted and transferred from CAFs to SCLC cells and induced DDP chemoresistance by targeting the miR-15a-5p/CCNE1 axis [65]. Simultaneously, lncRNAs can alter the sensitivity of cancer cells to chemotherapeutic drugs depending on the no-miRNA binding pathways. Beclin1 was a crucial factor during OXA-mediated autophagic cell death in CRC cells. CAF-derived exosomal lncRNA FAL1 has been found to act as the scaffold that promoted the interaction between Beclin1 and TRIM3 and induced the TRIM3-dependent Beclin1 polyubiquitination, resulting in inhibition of autophagy and chemoresistance to OXA [66]. LncRNA CCAL in CAF-derived exosomes has been confirmed to confer OXA resistance by interacting directly with mRNA stabilizing protein HuR (human antigen R) to increase β-catenin mRNA and protein expression [67]. Downregulation of DACT3-AS1 was significantly with worse prognosis of GC patients. CAF-derived exosomal DACT3-AS1 elevated the oxidative stress level through miR-181a-5p/SIRT1-mediated ferroptosis, enhance the sensitivity to OXA of GC cells [68].

CircRNAs

In addition to miRNAs and lncRNAs, CAFs-secreted circular RNAs (circRNAs) also take a novel role in the development of both inherent and acquired chemoresistance. CircRNAs are a type of non-coding RNA that forms a covalently closed continuous loop structure [69]. For instance, circZFR was highly expressed in DDP-resistant HCC cell lines, CAFs, and CAF-derived exosomes. In vitro and in vivo studies further indicated that CAFs-secreted exosomal circZFR enhanced the DDP resistance of HCC cells by inhibiting the STAT3/NF-κB pathway [70]. As a third-generation platinum drug, OXA plays a prominent role in cancer therapy. CircN4BP2L2 secreted by CAFs could positively bind to EIF4A3 to stimulate the PI3K/AKT/mTOR axis, correspondingly inducing the resistance to OXA in CRC [71]. In PDAC, CAF-derived exosomal circFARP1 also contributed to PDAC cell stemness and GEM resistance via the LIF/STAT3 axis [72]. Researchers have isolated and purified EVs from the plasma of PDAC patients by EV isolation kit, and detected that circBIRC6 was upregulated in plasma EVs and primary tumor tissues of oxaliplatin-resistant patients. Mechanically, circBIRC6 from CAF-derived EVs can directly bound to XRCC4, which encoded DNA ligase IV and elevated the crosstalk between XRCC4 and Small Ubiquitin Like Modifier 1 (SUMO1) in PDAC. Consequently, non-homologous end joining (NHEJ) dependent DNA repair was activated, resulting in the resistance to oxaliplatin [73].

Proteins

Proteins are also an important part in CAFs-secreted EVs, and multiple CAFs-secreted exosomal proteins also serve a pivotal role in cancer progression and therapy resistance. For instance, FOSL1 was enriched in CAFs-secreted exosomes and was transmitted to CRC cells, thus conferring resistance to OXA of CRC cells by transcriptionally activating integrin β4 (ITGB4) [74]. Vascular Endothelial Growth Factor A (VEGFA) can induce the proliferation and migration of vascular endothelia cell and is involved in tumor angiogenesis [75]. Intriguingly, VEGFA was elevated in exosomes derived by CAFs isolated from DDP-resistant CRC tissues. Functionally, CRC cells exhibited enhanced viability and DDP resistance after CAF-derived exosomal VEGFA treatment [76] (Table 1).

CAF-derived EVs in cancer targeted therapy resistance

Targeted therapy involves corresponding therapeutic drugs for targeting and inhibiting driver mutations that are characteristic of certain types of cancer [77, 78]. Multiple targeted therapy drugs have been applied in the treatment of diverse cancers, such as claudiximab for gastric cancer, TKIs for lung cancer and colorectal cancer, and trastuzumab targeting HER-2 for breast cancer [79]. However, the greatest obstacle to targeted cancer therapy is the inevitable emergence of drug resistance, which contributes to therapeutic failure and ultimate patient demise in genotype-matched precision medicine [80]. Multiple studies have indicated that EMT is connected with cancer progression and targeted therapy resistance [81]. It has been identified that CAF-derived EVs were involved in EMT induction through several biological processes including ECM remodeling, metabolic reprogramming, and oncogenic pathways activating [82]. In HCC, CAF-derived protein SPP1 was able to induce TKIs (sorafenib and lenvatinib) resistance. Mechanically, SPP1 induced EMT by activating the phosphorylation of the RAF/MAPK axis and PI3K/AKT/mTOR axis through the PKCα signalling pathway [83]. Similarly, Gremlin-1 from CAF-derived exosomes was proved to have an active role in regulating the EMT process and reducing the sensitivity of HCC cells to sorafenib via Wnt/β‐catenin and BMP signaling pathways. Clinically, patients with HCC exhibited a higher exosomal gremlin-1 level in serum, and serum gremlin-1 level could predict the sorafenib response of HCC patients [84]. In addition, CAFs-secreted CXCL12 conferred sorafenib resistance in HCC cells by upregulating FOLR1 expression in the mRNA level, and the CXCL12/CXCR4/FOLR1 was involved in sorafenib resistance of HCC [85]. Moreover, the in vitro experiment has demonstrated that miR-1228-3p carried by CAF-derived exosomes conferred sorafenib resistance in HCC9724 cells by modulating the PLAC8/PI3K/AKT axis [86]. Gao et al. have identified that CD63 + CAFs, a new CAF subset, can promote ERα downregulation and tamoxifen resistance in breast cancer by single‐cell sequencing. Mechanically, CD63 + CAFs can secrete exosomal miR-22 to induce tamoxifen resistance by directly targeting ERα and PTEN. Furthermore, the packaging of miR-22 into CD63 + CAF-derived exosomes was regulated by SFRS1, and CD63 stimulated STAT3 to maintain the phenotype and function of CD63 + CAFs. Inspiringly, the pharmacological inhibition of CD63 + CAFs with a CD63-neutralizing antibody or cRGD-miR-22-sponge nanoparticles can effective reverse tamoxifen resistance in breast cancer [87].

CAF-derived EVs in cancer radiotherapy resistance

Radiotherapy is one of the mainstays of cancer treatment, and radiotherapy is widely used in the treatment of multiple malignancies, such as anaplastic thyroid cancer (ATC), and ESCC [88, 89]. Approximately half of cancer patients will receive radiotherapy either alone or in combination with other therapies during their treatment [90]. However, radioresistance is still a critical challenge resulting in radiotherapy failure, cancer relapses, and poor prognosis in clinical practice [91]. Recent work has indicated that radiation can mediate the contents and secretion of functional exosomes from cancer cells and other cell types within tumor microenvironment, resulting in radiotherapy resistance and radiation-induced bystander effects [92, 93]. For instance, exosomal miR-143-3p has been estimated to confer radiation resistance by inducing M2 macrophage polarization in locally advanced ESCC [94]. CSCs in tumours are mostly resistant to conventional therapies including ionizing radiation, and a high dose of radiation is required to eradicate CSCs. CAF-derived exosomes promoted radiotherapy resistance through enhancing CRC stemness by activating TGF-β signalling pathway [95]. Chen et al. have isolated and purified exosomes from the plasma of CRC patients by ExoQuick Exosome Precipitation Kit, and detected that miR-590-3p was upregulated in patients with radioresistance compared with patients with radiosensitivity. Besides, ectopic upregulation of miR-590-3p was detected in CAF-derived exosomes compared to normal fibroblast-derived exosomes, and CAF-derived exosomal miR-590-3p decreased CRC sensitivity to radiation. Mechanically, miR-590-3p inhibited the expression of CLCA4 and mediated the phosphorylation of PI3K and AKT in CRC cells [96]. Similarly, both in vitro and in vivo studies have demonstrated that miR93-5p was also transferred by exosomes from CAFs to CRCs, and CAF-derived exosomal miR-93-5p downregulated FOXA1 and reversed the suppression of FOXA1 on TGFB3, subsequently contributing to radiation resistance [97]. In lung cancer, in vitro experiment has revealed that CAFs derived exosomal miR-196a-5p was upregulated and induced radioresistance by sponging NFKBIA and activating the NF-κB signalling pathway [98]. FAP-positive CAFs, a specific CAF subpopulation in ESCC have been found to transfer exosomal lncRNA AFAP1-AS1 to ESCC cells, and AFAP-AS1 promoted the repairment of damaged DNA, conferring radiotherapy resistance of ESCC cells [99] (Table 2).

Table 2 CAF-derived EVs in cancer radiotherapy resistance

Key cargo	Cancer type	Genes and pathways or biological processes	Radioresistance	Ref	
miR-143-3p	ESCC	M2 macrophage polarization	↑	[94]	
miR-590-3p	CRC	PI3K and AKT	↑	[96]	
miR-93-5p	CRC	FOXA1 and TGFB3	↑	[97]	
miR-196a-5p	LC	NFKBIA and NF-κB	↑	[98]	
lncRNA AFAP1-AS1	ESCC	DNA repairment	↑	[99]	

CAF-derived EVs in cancer immunotherapy resistance

Immunotherapy has ushered in a new era of cancer treatment and altered the therapeutic landscape for multiple human malignancies [100, 101]. The clinical goal of cancer immunotherapy is to prime the host immune system to provide passive or active immunity against malignant tumors [102, 103]. Rather than merely enhancing overall immunity, immunotherapy is also involved in the improvement of tumour immune microenvironment, potentially providing prolonged survival for cancer patients [104]. Various immunotherapies, including immune checkpoint inhibitors (ICIs), such as anti-PD-L1 drugs nivolumab and pembrolizumab, chimeric antigen receptor (CAR) T cells, tumor vaccines, and adoptive cell transfer (ACT), have shown promising curative effect on multiple cancers [105–108]. Despite tumour immunotherapy being approved for clinical use and achieving unprecedented results, resistance remains an obstacle to the application of immunotherapies [109]. Multiple studies have identified that CAFs were involved in mediating tumour immunotherapy resistance through immunosuppressive microenvironment generation, immune cell exclusion, and phenotype alternation [18]. For instance, signal-cell analysis revealed different CAF clusters, among which the cluster 0 CAFs (CAFs associated with ECM remodeling, collagen formation, and cell adhesion) upregulated the expression of PD-1 and cytotoxic T-lymphocyte associated protein 4 (CTLA4) on Treg cells, which, in turn, inhibited T cells function and induced immune resistance [110]. In breast cancer, CAFs inhibited ICIs efficiency by suppressing CD8 + T cell infiltration [111]. In HCC, prominent CD36 + CAFs exhibited high-level lipid metabolism and mediated macrophage migration inhibitory factor (MIF) expression by activating lipid peroxidation/p38/CEBPs axis. CD36 + CAFs also recruited CD33 + MDSCs, altering the tumour immune microenvironment [112]. CAF-derived EVs also play a critical role in regulating cancer immunotherapy resistance. For instance, CAF-derived exosomal miR-92 can significantly promote T cell apoptosis and confer immunotherapy resistance of breast cancer cells. Mechanically, miRNA-92 specifically bound to LATS2, which further interacted with YAP1, and chromatin immunoprecipitation confirmed that YAP1 could bind to the enhancer region of PD-L1 after nuclear translocation, promoting transcriptional activity [113]. CAFs can influence the efficacy of immunotherapy by interfering with the cytotoxic effects of T cells. In melanoma, studies have found that hypoxia can induce the secretion of immunosuppression factors such as TGF-β, VEGF, and PD-L1 from CAFs, which exerted an inhibitory effect on T cell-mediated cytotoxicity [114]. In CRC, the hypoxic microenvironment induced the production and excretion of circEIF3K-containing exosomes from CAFs compared with normoxic CAFs. CircEIF3 can reduce miR-214 to upregulate the expression of PD-L1, thereby inducing CRC cell proliferation, migration, metastasis, and immune escape [115]. In epithelial ovarian cancer (EOC), CAF-derived protein FMO2 facilitated the infiltration of lymphocytes. Higher level FMO2 was associated with worse prognosis in patients with similar levels of immune checkpoints such as PD-1 and PD-L1 suggesting that FMO2 could be a biomarker for predicting immunotherapy sensitivity [116]. In addition, it has been demonstrated that the CAF-derived EVs could mediate the immune escape of UBC by promoting PD-L1/PD-1 expression. Simultaneously, these EVs inhibited apoptosis in UBC cells, enhanced the invasion capability of T24 cells, and reduced the secretion of IFN-γ, IL-2, and TNF-α from CD8 + T cells, implying their potential role in inducing immunotherapy resistance of UBC [117].

Therapeutic potential of CAF-derived EVs

In the previous sections, we summarized the biological functions and detailed mechanisms of CAF-derived EVs in mediating cancer therapy resistance, providing evidence for the promising therapeutic potential of CAF-derived EVs in cancer management (Fig. 3). In this section, we will summarize and discuss the promising potential of CAF-derived EVs as clinical biomarkers and novel therapeutic targets for enhancing therapeutic efficacy.Fig. 3 CAF-derived EVs mediate cancer therapy resistance through complex mechanisms. CAF-derived EVs can deliver multiple cargoes to tumour cells, including miRNAs, lncRNAs, circRNAs and proteins. They can mediate the resistance to chemotherapy, targeted therapy, radiotherapy, and immunotherapy through multiple biological mechanisms, such as regulation of autophagy, EMT, and cancer stemness, metabolism, angiogenesis, DNA repair, immune infiltration, cell cycle, transcription and oncogenic signalling pathways

CAF-derived EVs as clinical biomarkers

Cancer is a highly heterogeneous disease involving diverse components, hence, developing effective cancer biomarkers is a critical way to represent cancer status and monitor cancer progression [118]. Liquid biopsy is a novel approach that collects biofluid specimens and provides more opportunities for early cancer diagnosis, prognosis prediction, and treatment efficacy evaluation [118, 119]. The large amounts of circulating EVs in biofluids produced by different cell types have become a critical component in liquid biopsies. For instance, Hoshino et al. have conducted a large-scale and comprehensive proteomic analysis of exosomes and exomeres from 426 human samples to develop novel diagnostic biomarkers [120]. Nowadays, a large number of clinical trials have been conducted to evaluate the therapeutic potential of EVs as diagnostic and prognostic biomarkers for diverse cancers. For instance, blood plasma samples from 420 lung cancer patients and 150 healthy controls were obtained to purify the exosomes in a recent clinical trial (ClinicalTrials.gov Identifier: NCT04529915). Deep-learning analysis of exosomes is performed to screen exosomal proteins for lung cancer early diagnosis and distinguish lung cancer patients in different clinical stages to improve the prognosis. In 2016, the first exosome-based liquid biopsy ExoDx™ Lung (ALK), was developed for the isolation and analysis of exosomal RNA from blood samples, which can effectively detect EML4-ALK mutations in NSCLC patients with 88% sensitivity and 100% specificity, thereby providing a more direct and sensitive approach to detect gene muutations than cfDNA [119]. The ExoDx Prostate IntelliScore (EPI), approved by the FDA, can effectively predict the risk of higher-grade prostate cancer for patients with PSA from 2 to 10 ng/mL by analyzing ERG, PCA3, and SPDEF RNA in exosomes [121]. Three independent, prospective, and multicenter clinical trials have reported that EPI can outperform the standard of care and serve as a novel biomarker for the early diagnosis of prostate cancer [122]. Another multicenter study has confirmed that GATA2 mRNA concentration in EVs in urine can effectively improve the detection of high-risk prostate cancer and may avoid unnecessary prostate biopsies [123]. In addition, MedOncAlyzer 170, a newly developed liquid biopsy system, has been developed for detecting exosomal RNA and ctDNA in a single trial. It can identify significant and functional mutations in multiple cancer types in a small volume (0.5 ml) of patient blood or plasma. Due to the unique way exosomes and ctDNA are formed, MedOncAlyzer 170 is accurate and highly sensitive to detect mutations at all stages of cancer progression and treatment [119].

Multiple experimental studies have evaluated the ectopic expression of diverse cargoes in CAF-derived EVs during cancer progression, and these cargoes are significantly correlated with clinical pathological features of cancer patients, thus highlighting the promising potential of CAF-derived EVs as biomarkers in the diagnosis and prognosis of various cancers. For instance, CAF-derived exosomal miR-196a is critically involved in HNC progression and chemoresistance, and plasma exosomal miR-196a levels were higher in HNC patients compared with healthy controls. Exosomal miR-196a levels were significantly higher in the plasma of patients with poor chemotherapeutic responses, larger tumor size, lymph node metastasis, and advanced tumor stage. Kaplan-Meier analysis and Cox proportional hazards regression analysis further confirmed that plasma exosomal miR-196a is a critical prognostic biomarker for HNC patients [124]. Similarly, miR-3188 is significantly downregulated in CAF-derived exosomes from HNC patients, and plasma miR-3188 levels were also downregulated in HNC patients and upregulated after tumour excision. A receiver operating characteristic (ROC) curve identified that plasma miR-3188 levels could serve as a diagnostic biomarker for HNC patients and low plasma miR-3188 expression was significantly correlated with larger tumor sizes and advanced TNM stage [125]. In HCC, miR-150-3p was significantly downregulated in CAF-derived exosomes and patients with low miR-150-3p levels in plasma exosomes had a worse prognosis [126]. Notably, several ongoing studies have been conducted to evaluate the potential of EVs as predictive biomarkers for cancer therapeutic efficacy. For instance, a previous study based on 18 melanoma and 8 NSCLC patients under anti PD-1 therapy has revealed that downregulation of PD-L1 mRNA in EVs was detected in patients with partial or complete immunotherapy response compared with those with progressive disease [127]. A recent clinical trial is designed to evaluate the response to immunotherapy (pablolizumab and nafulizumab) by measuring the PD-L1 and miRNA expression in plasma exosomes in pre- and post-treated NSCLC patients and correlates it with the treatment outcome (NCT04427475). Another ongoing clinical trial in Limoges (NCT03985696) is conducted to explore the expression of therapeutic targets (as CD20, PDL-1) in exosomes and immunotherapy resistance in patients with aggressive Non-Hodgkin B-cell lymphomas (B-NHL). Despite most of the current clinical trials being in Phase 0 or the initiation of recruitment, we believe that EVs will become promising and reliable clinical biomarkers and will eventually go to the clinic. In summary, diverse CAF-derived exosomal cargoes in body fluids across pan-cancers may function as non-invasive biomarkers in liquid biopsy for early diagnosis and clinical prediction.

CAF-derived EVs as therapeutic targets

Multiple lines of evidence have demonstrated that CAF-derived EVs actively participate in cancer tumorigenesis and progression. Hence, targeting CAFs and CAF-derived EVs has opened new avenues for cancer treatment. For instance, CAFs can promote intrahepatic cholangiocarcinoma progression by delivering miR-493-5p in EVs, highlighting that inhibiting miR-493-5p in CAFs may be a novel therapeutic strategy for intrahepatic cholangiocarcinoma treatment [128]. The CXCR4 antagonist motixafortide (BL-8040) has been found to inhibit the immunosuppressive CXCL12-CXCR4 axis mediated by FAP + CAFs and has been applied in combination with pembrolizumab and/or chemotherapy for the treatment of pancreatic cancer patients in phase II clinical trial (NCT02826486). CAF-derived ANXA6 EVs carry the ANXA6/LRP1/TSP1 complex to facilitate pancreatic cancer aggressiveness and depletion of ANXA6 in CAFs impaired complex formation and inhibited pancreatic cancer metastasis occurrence [129]. Inhibiting the biosynthesis and secretion of tumour-promoting EVs and blocking the endocytosis of tumour-promoting EVs by cancer cells have been investigated in multiple cancers recently. Several agents, such as tipifarnib and manumycin A have been reported to selectively inhibit tumour cell-released exosomes but exert no effects on normal cells [130]. Xi et al. have found that can stimulate ATM activation and facilitate autophagy-associated exosome release from CAFs to induce breast cancer cell invasion, and inhibition of oxidized ATM kinase by KU60019 (a small-molecule inhibitor of activated ATM) or shRNA effectively inhibits the exosome secretion from hypoxia-induced CAFs, subsequently inhibiting breast cancer progression [24]. Hence, specific inhibition of tumour-promoting EVs from CAFs may provide a novel method to inhibit cancer progression and reverse therapy resistance. In addition, the loss of specific cargoes in CAF-derived EVs may also contribute to cancer initiation and progression. For instance, miR-3188 was abnormally downregulated in CAF-derived exosomes in HNC, and loss of CAF-derived exosomal miR-3188 resulted in HNC progression in vivo and in vitro. Besides, miR-3188-loaded exosomes significantly inhibited tumor growth in vivo [125]. Hence, delivering anti-tumour agents by EVs may effectively inhibit tumour growth and improve patient prognosis. Inspiringly, several EV-delivered vaccines have entered clinical trials. For example, an ongoing phase II clinical trial (NCT01159288) is conducted to evaluate the safety and efficacy of dendritic cell-derived exosomes loaded with tumor antigens in 41 participants. Another early phase I clinical trial (NCT05559177) is designed to explore the therapeutic efficacy of chimeric exosomal tumor vaccines for recurrent or metastatic bladder cancer.

Perspectives and challenges

Multiple lines of evidence have revealed that CAF-derived EVs are critically involved in cancer therapy resistance with promising clinical significance and therapeutic potential. Targeting specific therapy resistance-associated CAF-derived EVs is a promising approach for overcoming cancer therapy resistance. In addition, CAF-derived EVs can function as noninvasive biomarkers in liquid biopsy, and may effectively improve the prediction of cancer patients’ therapeutic responses and prognosis [119]. Furthermore, engineered exosomes can function as a drug delivery system to deliver cargoes to specific cancer sites spatially and release the anti-cancer drugs temporally with enhanced efficacy and low side effects [131]. Recent studies have also illustrated that EVs may exert promising effects in repairing radiotherapy-related tissue damage by various mechanisms, such as promoting angiogenesis and inhibiting inflammation and fibrosis [132, 133]. Also, EVs have promising potential to treat cancer-related cachexia, which is a major complication of human malignancies and seriously affects the quality of life and prognosis of cancer patients [134]. Although promising progress has been achieved in illustrating the biological roles of CAF-derived EVs, several important unanswered questions and limitations should be resolved before the clinical application of CAF-derived EVs in cancer management.

Firstly, the categorization and classification of CAF subgroups lack a unified, standardized framework to address the diverse findings reported by different research teams, often within the same cancer category and utilizing comparable scRNA-seq or CyTOF methodologies. The subdivision and characterization of CAF subgroups appear subjective, leading to potential variations among observers [16]. Consequently, reaching a consensus on key biomarkers and hierarchical clustering patterns defining CAF subgroups through scRNA-seq or CyTOF analyses is imperative for the forthcoming period. Currently, there are still several challenges in applying scRNA-seq to investigate CAFs heterogeneity. For example, CAFs are difficult to isolate, because they are embedded in the ECM. Hence, CAFs are often under-represented in scRNA-seq investigation, and developing tissue-specific protocols for CAFs isolation is warranted [135]. Furthermore, the establishment of a standardized experimental platform featuring particular, specialized, and dependable tools and methodologies is essential for identifying, marking, segregating, cultivating, and functionally evaluating CAF subgroups both in artificial settings and within living organisms, akin to the protocols instituted for investigating immune cell populations. This standardization will facilitate the accurate delineation and description of CAF subgroups with designated functional roles and predictive significance, streamlining the design of tailored therapeutic strategies targeting specific CAF subpopulations or pathways in the future.

Secondly, the classifications for CAF-derived EVs remain elusive, with a recent study proposing isolation and characterization methods for six distinct EV subsets found in tissues. Despite these efforts, a universally accepted international categorization system for CAF-derived EVs is lacking, leaving doubts about the impact of inconsistent isolation and purification techniques on past findings. Future investigations ought to differentiate between various CAF-derived EV subsets and evaluate their anti-tumour potential. Additionally, the absence of systematic guidelines and procedures for the extraction, purification, and preservation of CAF-derived EVs poses a challenge to their clinical utilization. The employment of diverse isolation and purification approaches yields varying subpopulations of CAF-derived EVs possessing unique compositions, properties, and biological functions. Consequently, innovative standardized methodologies aligned with good manufacturing practices (GMP) are imperative for advancing CAF-derived EVs research.

Lastly, inhibiting the biogenesis and secretion of tumour-promoting CAF-derived EVs presents an innovative avenue for inhibiting cancer progression and therapy resistance, necessitating a profound comprehension of the biogenesis and release mechanisms of EVs. For instance, the Tspan family plays critical roles in regulating EV biogenesis, function, and targets, and Tspan proteins can regulate multifaced cancer behaviours and serve as clinical biomarkers [136]. Hence, targeting Tspan proteins may open new avenues for regulating EV biogenesis and functions and inhibiting tumour growth in anticancer therapeutic strategies [136, 137]. Nowadays, several EVs inhibitors have been investigated in cancer treatment, such as imipramine and pantethine for inhibiting EVs production, and bisindolylmaleimide I and macitentan for inhibiting EVs release [138]. Employing targeted siRNA or CRISPR/Cas9-loaded EVs, alongside multi-target pharmacological approaches to inhibit EV activity, also represents a novel therapeutic option for targeted CAF-derived EVs therapy. Nevertheless, challenges such as off-target effects, secure delivery modalities, nonspecific inhibition of non-cancerous EVs, and the triggering of compensatory pathways in EV formation and release pose significant hurdles. Beyond therapeutic efficacy, the reproducibility and efficiency of primary compounds for halting EV production necessitate further evaluation, especially since certain approved therapeutics with EV-targeting capabilities have displayed adverse effects in humans. For instance, imipramine, a tricyclic antidepressant, can result in undesirable outcomes, such as immune suppression and infection due to its interference with EVs formation via acid sphingomyelinase inhibition [139].

Conclusions

In conclusion, we discussed and summarized recent discoveries and research progress on the biological mechanisms of CAF-derived EVs in mediating therapy resistance in various cancers (Fig. 4). We further emphasized the clinical significance and implications of CAF-derived EVs in cancer management, which provides a novel direction for reversing cancer therapy resistance and improving patient prognosis. Due to the key role of CAF-derived EVs in mediating cancer therapy resistance, further in-depth studies are needed to illustrate the detailed mechanisms of CAF-derived EVs in cancer therapy failure and develop novel CAF-derived EVs-targeted therapeutic strategies to overcome cancer therapy resistance in the clinic.Fig. 4 Therapy resistance-related CAF-derived EVs in different cancers. CAF-derived EVs deliver miRNAs, lncRNAs, circRNAs and proteins to cancer cells, thus influence the therapy resistance of multiple cancer types, such as lung cancer, melanoma, and hepatocellular carcinoma. These cargoes in CAF-derived EVs may serve as novel therapeutic targets for reversing therapy resistance and clincal biomarkers for predicting therapy efficacy in cancer management

Abbreviations

ACT Adoptive cell transfer

ALK Anaplastic Lymphoma Kinase

APAF1 Apoptosis protease activating fator1

ATC Anaplastic thyroid cancer

CAFs Cancer-associated fibroblasts

CAR Chimeric antigen receptor

cfDNA Cell free DNA

circRNAs Circular RNAs

CRC Colorectal cancer

CSCs Cancer stem cells

CTLA4 Cytotoxic T-lymphocyte associated protein 4

DDP Cisplatin

DOX Doxorubicin

DTX Docetaxel

ECM Extracellular matrix

EMT Epithelial-mesenchymal transition

EOC Epithelial ovarian cancer

EPI ExoDx Prostate IntelliScore

ESCC Esophageal squamous cell carcinoma

EVs Extracellular vesicles

FGF5 Fibroblast growth factor 5

FMO2 Flavin containing monooxygenase 2

FOSL1 Recombinant FOS Like Antigen 1

GC Gastric Cancer

GEM Gemcitabine

GMP Good manufacturing practices

HCC Hepatocellular carcinoma

HGF Hepatocyte growth factor

HNC Head and Neck Cancer

HuR Human antigen R

ICIs Immune Checkpoint Inhibitors

ITGB4 Integrin β4

LncRNAs Long non-coding RNAs

LSCC Laryngeal squamous cell carcinoma

MIF Migration inhibitory factor

miRNAs MicroRNAs

M-MDSCs Monocytic myeloid-derived suppressor cells

MTX Methotrexate

ncRNAs Non-coding RNAs

NFs Normal Fibroblasts

NHEJ Non-homologous end joining

NSCLC Non-small cell lung cancer

OXA Oxaliplatin

PDAC Pancreatic Ductal Adenocarcinoma

PIAT PNI-associated transcript

PTX paclitaxel

SCC squamous cell carcinoma

SCLC small cell lung cancer

shRNA short hairpin RNA

SNAIL Snail zinc finger transcription factor

SPP1 secreted phosphoprotein 1

SUMO1 Small Ubiquitin Like Modifier 1

TKIs Tyrosine Kinase Inhibitors

TP53INP1 Tumor protein p53-inducible nuclear protein 1

UBC urothelial bladder cancer

VEGFA Vascular Endothelial Growth Factor A

YBX1 Recombinant Y-Box Binding Protein 1

Acknowledgements

Not applicable.

Authors’ contributions

ZJL, and TL contributed to conceive, design and revision of the manuscript sections. ZJL, and GQL wrote the manuscript. KJ and GQL designed figures and created Tables. TL and ZH L supervised the manuscript by providing critical feedbacks and revisions. The authors read and approved the final manuscript.

Funding

This study was supported by grants from National Natural Science Foundation of China (NO. 81871783 and 82072441), Hunan Outstanding Youth Fund Project Grant (NO. 2022JJ10095).

Availability of data and materials

Not applicable.

Data availability

Not Applicable.

Declarations

Ethics approval and consent to participate

No datasets were generated or analysed during the current study.

Consent for publication

All authors consent to publication.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Zhengjun Lin and Guoqing Li contributed equally to this work and share the first authorship.
==== Refs
References

1. Siegel RL Miller KD Wagle NS Jemal A Cancer statistics, 2023 CA Cancer J Clin 2023 73 1 17 48 10.3322/caac.21763 36633525
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.36633525 10.3322/caac.21763
2. Gao H Xi Z Dai J Xue J Guan X Zhao L Chen Z Xing F Drug resistance mechanisms and treatment strategies mediated by ubiquitin-specific proteases (USPs) in cancers: new directions and therapeutic options Mol Cancer 2024 23 1 88 10.1186/s12943-024-02005-y 38702734
Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L, Chen Z, Xing F. Drug resistance mechanisms and treatment strategies mediated by ubiquitin-specific proteases (USPs) in cancers: new directions and therapeutic options. Mol Cancer. 2024;23(1):88.38702734 10.1186/s12943-024-02005-y
3. Kim TK Vandsemb EN Herbst RS Chen L Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities Nat Rev Drug Discov 2022 21 7 529 40 10.1038/s41573-022-00493-5 35701637
Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov. 2022;21(7):529–40.35701637 10.1038/s41573-022-00493-5
4. Robertson BM, Fane ME, Weeraratna AT, Rebecca VW. Determinants of resistance and response to melanoma therapy. Nat Cancer. 2024;5(7):964–82.
5. Andrei L Kasas S Ochoa Garrido I Stankovic T Suarez Korsnes M Vaclavikova R Assaraf YG Pesic M Advanced technological tools to study multidrug resistance in cancer Drug Resist Updat 2020 48 100658 10.1016/j.drup.2019.100658 31678863
Andrei L, Kasas S, Ochoa Garrido I, Stankovic T, Suarez Korsnes M, Vaclavikova R, Assaraf YG, Pesic M. Advanced technological tools to study multidrug resistance in cancer. Drug Resist Updat. 2020;48:100658.31678863 10.1016/j.drup.2019.100658
6. Wang X Jiang W Du Y Zhu D Zhang J Fang C Yan F Chen ZS Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer Drug Resist Updat 2022 65 100884 10.1016/j.drup.2022.100884 36252360
Wang X, Jiang W, Du Y, Zhu D, Zhang J, Fang C, Yan F, Chen ZS. Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer. Drug Resist Updat. 2022;65:100884.36252360 10.1016/j.drup.2022.100884
7. Chan YT Wu J Lu Y Li Q Feng Z Xu L Yuan H Xing T Zhang C Tan HY Feng Y Wang N Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC Mol Cancer 2024 23 1 74 10.1186/s12943-024-01988-y 38582885
Chan YT, Wu J, Lu Y, Li Q, Feng Z, Xu L, Yuan H, Xing T, Zhang C, Tan HY, Feng Y, Wang N. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC. Mol Cancer. 2024;23(1):74.38582885 10.1186/s12943-024-01988-y
8. Zhang H Dong X Ding X Liu G Yang F Song Q Sun H Chen G Li S Li Y Wang M Guo T Zhang Z Li B Yang L Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/beta-catenin signal pathway J Transl Med 2023 21 1 900 10.1186/s12967-023-04613-6 38082327
Zhang H, Dong X, Ding X, Liu G, Yang F, Song Q, Sun H, Chen G, Li S, Li Y, Wang M, Guo T, Zhang Z, Li B, Yang L. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/beta-catenin signal pathway. J Transl Med. 2023;21(1):900.38082327 10.1186/s12967-023-04613-6
9. Zhang H Yang J Song Q Ding X Sun F Yang L UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway Acta Biochim Biophys Sin (Shanghai) 2024 56 2 199 209 10.3724/abbs.2024014 38298057
Zhang H, Yang J, Song Q, Ding X, Sun F, Yang L. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway. Acta Biochim Biophys Sin (Shanghai). 2024;56(2):199–209.38298057 10.3724/abbs.2024014
10. Soumoy L Ghanem GE Saussez S Journe F Bufalin for an innovative therapeutic approach against cancer Pharmacol Res 2022 184 106442 10.1016/j.phrs.2022.106442 36096424
Soumoy L, Ghanem GE, Saussez S, Journe F. Bufalin for an innovative therapeutic approach against cancer. Pharmacol Res. 2022;184:106442.36096424 10.1016/j.phrs.2022.106442
11. Zhang W Fan Y Zhang J Shi D Yuan J Ashrafizadeh M Li W Hu M Abd El-Aty AM Hacimuftuoglu A Linnebacher M Cheng Y Li W Fang S Gong P Zhang X Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer Drug Resist Updat 2023 71 101005 10.1016/j.drup.2023.101005 37647746
Zhang W, Fan Y, Zhang J, Shi D, Yuan J, Ashrafizadeh M, Li W, Hu M, Abd El-Aty AM, Hacimuftuoglu A, Linnebacher M, Cheng Y, Li W, Fang S, Gong P, Zhang X. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer. Drug Resist Updat. 2023;71:101005.37647746 10.1016/j.drup.2023.101005
12. Wu SY Fu T Jiang YZ Shao ZM Natural killer cells in cancer biology and therapy Mol Cancer 2020 19 1 120 10.1186/s12943-020-01238-x 32762681
Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.32762681 10.1186/s12943-020-01238-x
13. Barry ST Gabrilovich DI Sansom OJ Campbell AD Morton JP Therapeutic targeting of tumour myeloid cells Nat Rev Cancer 2023 23 4 216 37 10.1038/s41568-022-00546-2 36747021
Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP. Therapeutic targeting of tumour myeloid cells. Nat Rev Cancer. 2023;23(4):216–37.36747021 10.1038/s41568-022-00546-2
14. Lavie D Ben-Shmuel A Erez N Scherz-Shouval R Cancer-associated fibroblasts in the single-cell era Nat Cancer 2022 3 7 793 807 10.1038/s43018-022-00411-z 35883004
Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3(7):793–807.35883004 10.1038/s43018-022-00411-z
15. Chen Y McAndrews KM Kalluri R Clinical and therapeutic relevance of cancer-associated fibroblasts Nat Rev Clin Oncol 2021 18 12 792 804 10.1038/s41571-021-00546-5 34489603
Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792–804.34489603 10.1038/s41571-021-00546-5
16. Biffi G Tuveson DA Diversity and Biology of Cancer-Associated fibroblasts Physiol Rev 2021 101 1 147 76 10.1152/physrev.00048.2019 32466724
Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated fibroblasts. Physiol Rev. 2021;101(1):147–76.32466724 10.1152/physrev.00048.2019
17. Li C Teixeira AF Zhu HJ Ten Dijke, Cancer associated-fibroblast-derived exosomes in cancer progression Mol Cancer 2021 20 1 154 10.1186/s12943-021-01463-y 34852849
Li C, Teixeira AF, Zhu HJ. Ten Dijke, Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 2021;20(1):154.34852849 10.1186/s12943-021-01463-y
18. Zhang H Yue X Chen Z Liu C Wu W Zhang N Liu Z Yang L Jiang Q Cheng Q Luo P Liu G Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials Mol Cancer 2023 22 1 159 10.1186/s12943-023-01860-5 37784082
Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, Liu Z, Yang L, Jiang Q, Cheng Q, Luo P, Liu G. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159.37784082 10.1186/s12943-023-01860-5
19. Sahai E Astsaturov I Cukierman E DeNardo DG Egeblad M Evans RM Fearon D Greten FR Hingorani SR Hunter T Hynes RO Jain RK Janowitz T Jorgensen C Kimmelman AC Kolonin MG Maki RG Powers RS Pure E Ramirez DC Scherz-Shouval R Sherman MH Stewart S Tlsty TD Tuveson DA Watt FM Weaver V Weeraratna AT Werb Z A framework for advancing our understanding of cancer-associated fibroblasts Nat Rev Cancer 2020 20 3 174 86 10.1038/s41568-019-0238-1 31980749
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Pure E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174–86.31980749 10.1038/s41568-019-0238-1
20. Zhong D Wang Z Ye Z Wang Y Cai X Cancer-derived exosomes as novel biomarkers in metastatic gastrointestinal cancer Mol Cancer 2024 23 1 67 10.1186/s12943-024-01948-6 38561768
Zhong D, Wang Z, Ye Z, Wang Y, Cai X. Cancer-derived exosomes as novel biomarkers in metastatic gastrointestinal cancer. Mol Cancer. 2024;23(1):67.38561768 10.1186/s12943-024-01948-6
21. van Niel G D’Angelo G Raposo G Shedding light on the cell biology of extracellular vesicles Nat Rev Mol Cell Biol 2018 19 4 213 28 10.1038/nrm.2017.125 29339798
van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–28.29339798 10.1038/nrm.2017.125
22. Han T Chen L Li K Hu Q Zhang Y You X Han L Chen T Li K Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer? Mol Cancer 2023 22 1 197 10.1186/s12943-023-01891-y 38053070
Han T, Chen L, Li K, Hu Q, Zhang Y, You X, Han L, Chen T, Li K. Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer? Mol Cancer. 2023;22(1):197.38053070 10.1186/s12943-023-01891-y
23. Kalluri R LeBleu VS The biology, function, and biomedical applications of exosomes Science 2020 367 6478 640 10.1126/science.aau6977
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):640.10.1126/science.aau6977
24. Xi L Peng M Liu S Liu Y Wan X Hou Y Qin Y Yang L Chen S Zeng H Teng Y Cui X Liu M Hypoxia-stimulated ATM activation regulates autophagy-associated exosome release from cancer-associated fibroblasts to promote cancer cell invasion J Extracell Vesicles 2021 10 11 e12146 10.1002/jev2.12146 34545708
Xi L, Peng M, Liu S, Liu Y, Wan X, Hou Y, Qin Y, Yang L, Chen S, Zeng H, Teng Y, Cui X, Liu M. Hypoxia-stimulated ATM activation regulates autophagy-associated exosome release from cancer-associated fibroblasts to promote cancer cell invasion. J Extracell Vesicles. 2021;10(11):e12146.34545708 10.1002/jev2.12146
25. Fang T Lv H Lv G Li T Wang C Han Q Yu L Su B Guo L Huang S Cao D Tang L Tang S Wu M Yang W Wang H Tumor-derived exosomal mir-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer Nat Commun 2018 9 1 191 10.1038/s41467-017-02583-0 29335551
Fang T, Lv H, Lv G, Li T, Wang C, Han Q, Yu L, Su B, Guo L, Huang S, Cao D, Tang L, Tang S, Wu M, Yang W, Wang H. Tumor-derived exosomal mir-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018;9(1):191.29335551 10.1038/s41467-017-02583-0
26. Zheng S Hu C Lin Q Li T Li G Tian Q Zhang X Huang T Ye Y He R Chen C Zhou Y Chen R Extracellular vesicle-packaged PIAT from cancer-associated fibroblasts drives neural remodeling by mediating m5C modification in pancreatic cancer mouse models Sci Transl Med 2024 16 756 eadi0178 10.1126/scitranslmed.adi0178 39018369
Zheng S, Hu C, Lin Q, Li T, Li G, Tian Q, Zhang X, Huang T, Ye Y, He R, Chen C, Zhou Y, Chen R. Extracellular vesicle-packaged PIAT from cancer-associated fibroblasts drives neural remodeling by mediating m5C modification in pancreatic cancer mouse models. Sci Transl Med. 2024;16(756):eadi0178.39018369 10.1126/scitranslmed.adi0178
27. Holohan C Van Schaeybroeck S Longley DB Johnston PG Cancer drug resistance: an evolving paradigm Nat Rev Cancer 2013 13 10 714 26 10.1038/nrc3599 24060863
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26.24060863 10.1038/nrc3599
28. Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.
29. Fang Y Zhou W Rong Y Kuang T Xu X Wu W Wang D Lou W Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer Exp Cell Res 2019 383 1 111543 10.1016/j.yexcr.2019.111543 31374207
Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu W, Wang D, Lou W. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Exp Cell Res. 2019;383(1):111543.31374207 10.1016/j.yexcr.2019.111543
30. Czekay RP Cheon DJ Samarakoon R Kutz SM Higgins PJ Cancer-Associated fibroblasts: mechanisms of Tumor Progression and Novel therapeutic targets Cancers (Basel) 2022 14 5 1231 10.3390/cancers14051231 35267539
Czekay RP, Cheon DJ, Samarakoon R, Kutz SM, Higgins PJ. Cancer-Associated fibroblasts: mechanisms of Tumor Progression and Novel therapeutic targets. Cancers (Basel). 2022;14(5):1231.35267539 10.3390/cancers14051231
31. Sun Z Shi K Yang S Liu J Zhou Q Wang G Song J Li Z Zhang Z Yuan W Effect of exosomal miRNA on cancer biology and clinical applications Mol Cancer 2018 17 1 147 10.1186/s12943-018-0897-7 30309355
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z, Yuan W. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147.30309355 10.1186/s12943-018-0897-7
32. Zhang T Zhang P Li HX CAFs-Derived exosomal miRNA-130a confers Cisplatin Resistance of NSCLC cells through PUM2-Dependent packaging Int J Nanomed 2021 16 561 77 10.2147/IJN.S271976
Zhang T, Zhang P, Li HX. CAFs-Derived exosomal miRNA-130a confers Cisplatin Resistance of NSCLC cells through PUM2-Dependent packaging. Int J Nanomed. 2021;16:561–77.10.2147/IJN.S271976
33. Shi L Zhu W Huang Y Zhuo L Wang S Chen S Zhang B Ke B Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer Clin Transl Med 2022 12 7 e989 10.1002/ctm2.989 35857905
Shi L, Zhu W, Huang Y, Zhuo L, Wang S, Chen S, Zhang B, Ke B. Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer. Clin Transl Med. 2022;12(7):e989.35857905 10.1002/ctm2.989
34. Zhao Q Huang L Qin G Qiao Y Ren F Shen C Wang S Liu S Lian J Wang D Yu W Zhang Y Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma Cancer Lett 2021 518 35 48 10.1016/j.canlet.2021.06.009 34139285
Zhao Q, Huang L, Qin G, Qiao Y, Ren F, Shen C, Wang S, Liu S, Lian J, Wang D, Yu W, Zhang Y. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35–48.34139285 10.1016/j.canlet.2021.06.009
35. Zhang H-W Shi Y Liu J-B Wang H-M Wang P-Y Wu Z-J Li L Gu L-P Cao P-S Wang G-R Ma Y-S Fu D Cancer-associated fibroblast-derived exosomal microRNA-24-3p enhances colon cancer cell resistance to MTX by down-regulating CDX2/HEPH axis J Cell Mol Med 2021 25 8 3699 713 10.1111/jcmm.15765 33621425
Zhang H-W, Shi Y, Liu J-B, Wang H-M, Wang P-Y, Wu Z-J, Li L, Gu L-P, Cao P-S, Wang G-R, Ma Y-S, Fu D. Cancer-associated fibroblast-derived exosomal microRNA-24-3p enhances colon cancer cell resistance to MTX by down-regulating CDX2/HEPH axis. J Cell Mol Med. 2021;25(8):3699–713.33621425 10.1111/jcmm.15765
36. Mosca L Ilari A Fazi F Assaraf YG Colotti G Taxanes in cancer treatment: activity, chemoresistance and its overcoming Drug Resist Updat 2021 54 100742 10.1016/j.drup.2020.100742 33429249
Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54:100742.33429249 10.1016/j.drup.2020.100742
37. Shan G Gu J Zhou D Li L Cheng W Wang Y Tang T Wang X Cancer-associated fibroblast-secreted exosomal mir-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-β signaling pathway Exp Mol Med 2020 52 11 1809 22 10.1038/s12276-020-0431-z 33144675
Shan G, Gu J, Zhou D, Li L, Cheng W, Wang Y, Tang T, Wang X. Cancer-associated fibroblast-secreted exosomal mir-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-β signaling pathway. Exp Mol Med. 2020;52(11):1809–22.33144675 10.1038/s12276-020-0431-z
38. Sun L Ke M Yin M Zeng Y Ji Y Hu Y Fu S Zhang C Extracellular vesicle-encapsulated microRNA-296-3p from cancer-associated fibroblasts promotes ovarian cancer development through regulation of the PTEN/AKT and SOCS6/STAT3 pathways Cancer Sci 2024 115 1 155 69 10.1111/cas.16014 37972389
Sun L, Ke M, Yin M, Zeng Y, Ji Y, Hu Y, Fu S, Zhang C. Extracellular vesicle-encapsulated microRNA-296-3p from cancer-associated fibroblasts promotes ovarian cancer development through regulation of the PTEN/AKT and SOCS6/STAT3 pathways. Cancer Sci. 2024;115(1):155–69.37972389 10.1111/cas.16014
39. Au Yeung CL Co NN Tsuruga T Yeung TL Kwan SY Leung CS Li Y Lu ES Kwan K Wong KK Schmandt R Lu KH Mok SC Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1 Nat Commun 2016 7 11150 10.1038/ncomms11150 27021436
Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, Schmandt R, Lu KH, Mok SC. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150.27021436 10.1038/ncomms11150
40. Jiang X Stockwell BR Conrad M Ferroptosis: mechanisms, biology and role in disease Nat Rev Mol Cell Biol 2021 22 4 266 82 10.1038/s41580-020-00324-8 33495651
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82.33495651 10.1038/s41580-020-00324-8
41. Zhang C Liu X Jin S Chen Y Guo R Ferroptosis in cancer therapy: a novel approach to reversing drug resistance Mol Cancer 2022 21 1 47 10.1186/s12943-022-01530-y 35151318
Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47.35151318 10.1186/s12943-022-01530-y
42. Zhang H Deng T Liu R Ning T Yang H Liu D Zhang Q Lin D Ge S Bai M Wang X Zhang L Li H Yang Y Ji Z Wang H Ying G Ba Y CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer Mol Cancer 2020 19 1 43 10.1186/s12943-020-01168-8 32106859
Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D, Zhang Q, Lin D, Ge S, Bai M, Wang X, Zhang L, Li H, Yang Y, Ji Z, Wang H, Ying G, Ba Y. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. 2020;19(1):43.32106859 10.1186/s12943-020-01168-8
43. Qi R Bai Y Li K Liu N Xu Y Dal E Wang Y Lin R Wang H Liu Z Li X Wang X Shi B Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs Drug Resist Updat 2023 68 100960 10.1016/j.drup.2023.100960 37003125
Qi R, Bai Y, Li K, Liu N, Xu Y, Dal E, Wang Y, Lin R, Wang H, Liu Z, Li X, Wang X, Shi B. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resist Updat. 2023;68:100960.37003125 10.1016/j.drup.2023.100960
44. Zhao J Shen J Mao L Yang T Liu J Hongbin S Cancer associated fibroblast secreted Mir-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer Oncogene 2024 43 27 2104 14 10.1038/s41388-024-03057-6 38769193
Zhao J, Shen J, Mao L, Yang T, Liu J, Hongbin S. Cancer associated fibroblast secreted Mir-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer. Oncogene. 2024;43(27):2104–14.38769193 10.1038/s41388-024-03057-6
45. Lin Z Lu S Xie X Yi X Huang H Noncoding RNAs in drug-resistant pancreatic cancer: a review Biomed Pharmacother 2020 131 110768 10.1016/j.biopha.2020.110768 33152930
Lin Z, Lu S, Xie X, Yi X, Huang H. Noncoding RNAs in drug-resistant pancreatic cancer: a review. Biomed Pharmacother. 2020;131:110768.33152930 10.1016/j.biopha.2020.110768
46. Cui Y Zhang S Hu X Gao F Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling Bioengineered 2022 13 5 12462 74 10.1080/21655979.2022.2076008 35587143
Cui Y, Zhang S, Hu X, Gao F. Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling. Bioengineered. 2022;13(5):12462–74.35587143 10.1080/21655979.2022.2076008
47. Schuth S Le Blanc S Krieger TG Jabs J Schenk M Giese NA Büchler MW Eils R Conrad C Strobel O Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system J Exp Clin Cancer Res 2022 41 1 312 10.1186/s13046-022-02519-7 36273171
Schuth S, Le Blanc S, Krieger TG, Jabs J, Schenk M, Giese NA, Büchler MW, Eils R, Conrad C, Strobel O. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J Exp Clin Cancer Res. 2022;41(1):312.36273171 10.1186/s13046-022-02519-7
48. Richards KE, Xiao W, Hill RT. On Behalf of the Usc Pancreas Research, Cancer-Associated fibroblasts Confer Gemcitabine Resistance to Pancreatic Cancer cells through PTEN-Targeting miRNAs in Exosomes. Cancers. 2022;14(11):2812.
49. Erin N Grahovac J Brozovic A Efferth T Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance Drug Resist Updat 2020 53 100715 10.1016/j.drup.2020.100715 32679188
Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.32679188 10.1016/j.drup.2020.100715
50. Richards KE Zeleniak AE Fishel ML Wu J Littlepage LE Hill R Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells Oncogene 2017 36 13 1770 8 10.1038/onc.2016.353 27669441
Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE, Hill R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 2017;36(13):1770–8.27669441 10.1038/onc.2016.353
51. Shan G Zhou X Gu J Zhou D Cheng W Wu H Wang Y Tang T Wang X Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN Cell Oncol (Dordr) 2021 44 1 45 59 10.1007/s13402-020-00500-0 33423167
Shan G, Zhou X, Gu J, Zhou D, Cheng W, Wu H, Wang Y, Tang T, Wang X. Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN. Cell Oncol (Dordr). 2021;44(1):45–59.33423167 10.1007/s13402-020-00500-0
52. Hu JL Wang W Lan XL Zeng ZC Liang YS Yan YR Song FY Wang FF Zhu XH Liao WJ Liao WT Ding YQ Liang L CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer Mol Cancer 2019 18 1 91 10.1186/s12943-019-1019-x 31064356
Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, Song FY, Wang FF, Zhu XH, Liao WJ, Liao WT, Ding YQ, Liang L. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18(1):91.31064356 10.1186/s12943-019-1019-x
53. Wigerup C Påhlman S Bexell D Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer Pharmacol Ther 2016 164 152 69 10.1016/j.pharmthera.2016.04.009 27139518
Wigerup C, Påhlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016;164:152–69.27139518 10.1016/j.pharmthera.2016.04.009
54. Deng K Zou F Xu J Xu D Luo Z Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer Mol Carcinog 2024 63 3 524 37 10.1002/mc.23668 38197482
Deng K, Zou F, Xu J, Xu D, Luo Z. Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer. Mol Carcinog. 2024;63(3):524–37.38197482 10.1002/mc.23668
55. Icard P Shulman S Farhat D Steyaert JM Alifano M Lincet H How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat 2018 38 1 11 10.1016/j.drup.2018.03.001 29857814
Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1–11.29857814 10.1016/j.drup.2018.03.001
56. Ganapathy-Kanniappan S Geschwind JF Tumor glycolysis as a target for cancer therapy: progress and prospects Mol Cancer 2013 12 152 10.1186/1476-4598-12-152 24298908
Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.24298908 10.1186/1476-4598-12-152
57. Kunou S Shimada K Takai M Sakamoto A Aoki T Hikita T Kagaya Y Iwamoto E Sanada M Shimada S Hayakawa F Oneyama C Kiyoi H Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma Oncogene 2021 40 23 3989 4003 10.1038/s41388-021-01829-y 33994542
Kunou S, Shimada K, Takai M, Sakamoto A, Aoki T, Hikita T, Kagaya Y, Iwamoto E, Sanada M, Shimada S, Hayakawa F, Oneyama C, Kiyoi H. Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. Oncogene. 2021;40(23):3989–4003.33994542 10.1038/s41388-021-01829-y
58. Wu B Shi X Jiang M Liu H Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment Mol Cancer 2023 22 1 38 10.1186/s12943-023-01748-4 36810098
Wu B, Shi X, Jiang M, Liu H. Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Mol Cancer. 2023;22(1):38.36810098 10.1186/s12943-023-01748-4
59. Zhuang J Shen L Li M Sun J Hao J Li J Zhu Z Ge S Zhang D Guo H Huang R Yan J Cancer-Associated fibroblast-derived miR-146a-5p generates a Niche that promotes bladder Cancer Stemness and Chemoresistance Cancer Res 2023 83 10 1611 27 10.1158/0008-5472.CAN-22-2213 36939397
Zhuang J, Shen L, Li M, Sun J, Hao J, Li J, Zhu Z, Ge S, Zhang D, Guo H, Huang R, Yan J. Cancer-Associated fibroblast-derived miR-146a-5p generates a Niche that promotes bladder Cancer Stemness and Chemoresistance. Cancer Res. 2023;83(10):1611–27.36939397 10.1158/0008-5472.CAN-22-2213
60. Wang M Zhuoma C Liu X Huang Q Cai G Sang G Zhou L Du H Wu C Loss of exosomal miR-34c-5p in cancer-associated fibroblast for the maintenance of stem-like phenotypes of laryngeal cancer cells Head Neck 2022 44 11 2437 51 10.1002/hed.27155 35866307
Wang M, Zhuoma C, Liu X, Huang Q, Cai G, Sang G, Zhou L, Du H, Wu C. Loss of exosomal miR-34c-5p in cancer-associated fibroblast for the maintenance of stem-like phenotypes of laryngeal cancer cells. Head Neck. 2022;44(11):2437–51.35866307 10.1002/hed.27155
61. Ferrer J Dimitrova N Transcription regulation by long non-coding RNAs: mechanisms and disease relevance Nat Rev Mol Cell Biol 2024 25 5 396 415 10.1038/s41580-023-00694-9 38242953
Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance. Nat Rev Mol Cell Biol. 2024;25(5):396–415.38242953 10.1038/s41580-023-00694-9
62. Luo G Zhang Y Wu Z Zhang L Liang C Chen X Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis Acta Biochim Biophys Sin 2021 53 5 558 66 10.1093/abbs/gmab023 33720323
Luo G, Zhang Y, Wu Z, Zhang L, Liang C, Chen X. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis. Acta Biochim Biophys Sin. 2021;53(5):558–66.33720323 10.1093/abbs/gmab023
63. Hu JH Tang HN Wang YH Cancer-associated fibroblast exosome LINC00355 promotes epithelial-mesenchymal transition and chemoresistance in colorectal cancer through the miR-34b-5p/CRKL axis Cancer Gene Ther 2024 31 2 259 72 10.1038/s41417-023-00700-4 38052858
Hu JH, Tang HN, Wang YH. Cancer-associated fibroblast exosome LINC00355 promotes epithelial-mesenchymal transition and chemoresistance in colorectal cancer through the miR-34b-5p/CRKL axis. Cancer Gene Ther. 2024;31(2):259–72.38052858 10.1038/s41417-023-00700-4
64. Gao Q Fang X Chen Y Li Z Wang M Exosomal lncRNA UCA1 from cancer-associated fibroblasts enhances chemoresistance in vulvar squamous cell carcinoma cells J Obstet Gynaecol Res 2021 47 1 73 87 10.1111/jog.14418 32812305
Gao Q, Fang X, Chen Y, Li Z, Wang M. Exosomal lncRNA UCA1 from cancer-associated fibroblasts enhances chemoresistance in vulvar squamous cell carcinoma cells. J Obstet Gynaecol Res. 2021;47(1):73–87.32812305 10.1111/jog.14418
65. Sun Y Hao G Zhuang M Lv H Liu C Su K MEG3 LncRNA from Exosomes released from Cancer-Associated fibroblasts enhances Cisplatin Chemoresistance in SCLC via a MiR-15a-5p/CCNE1 Axis Yonsei Med J 2022 63 3 229 40 10.3349/ymj.2022.63.3.229 35184425
Sun Y, Hao G, Zhuang M, Lv H, Liu C, Su K. MEG3 LncRNA from Exosomes released from Cancer-Associated fibroblasts enhances Cisplatin Chemoresistance in SCLC via a MiR-15a-5p/CCNE1 Axis. Yonsei Med J. 2022;63(3):229–40.35184425 10.3349/ymj.2022.63.3.229
66. Zhu S Mao J Zhang X Wang P Zhou Y Tong J Peng H Yang B Fu Q CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer Dig Liver Dis 2024 56 2 330 42 10.1016/j.dld.2023.06.010 37400281
Zhu S, Mao J, Zhang X, Wang P, Zhou Y, Tong J, Peng H, Yang B, Fu Q. CAF-derived exosomal lncRNA FAL1 promotes chemoresistance to oxaliplatin by regulating autophagy in colorectal cancer. Dig Liver Dis. 2024;56(2):330–42.37400281 10.1016/j.dld.2023.06.010
67. Deng X Ruan H Zhang X Xu X Zhu Y Peng H Zhang X Kong F Guan M Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells Int J Cancer 2020 146 6 1700 16 10.1002/ijc.32608 31381140
Deng X, Ruan H, Zhang X, Xu X, Zhu Y, Peng H, Zhang X, Kong F, Guan M. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer. 2020;146(6):1700–16.31381140 10.1002/ijc.32608
68. Qu X Liu B Wang L Liu L Zhao W Liu C Ding J Zhao S Xu B Yu H Zhang X Chai J Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer Drug Resist Updat 2023 68 100936 10.1016/j.drup.2023.100936 36764075
Qu X, Liu B, Wang L, Liu L, Zhao W, Liu C, Ding J, Zhao S, Xu B, Yu H, Zhang X, Chai J. Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer. Drug Resist Updat. 2023;68:100936.36764075 10.1016/j.drup.2023.100936
69. Chen LL The expanding regulatory mechanisms and cellular functions of circular RNAs Nat Rev Mol Cell Biol 2020 21 8 475 90 10.1038/s41580-020-0243-y 32366901
Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475–90.32366901 10.1038/s41580-020-0243-y
70. Zhou Y Tang W Zhuo H Zhu D Rong D Sun J Song J Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/ nuclear factor -kappa B (NF-κB) pathway Bioengineered 2022 13 3 4786 97 10.1080/21655979.2022.2032972 35139763
Zhou Y, Tang W, Zhuo H, Zhu D, Rong D, Sun J, Song J. Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/ nuclear factor -kappa B (NF-κB) pathway. Bioengineered. 2022;13(3):4786–97.35139763 10.1080/21655979.2022.2032972
71. Qu Z Yang KD Luo BH Zhang F CAFs-secreted exosomal cricN4BP2L2 promoted colorectal cancer stemness and chemoresistance by interacting with EIF4A3 Exp Cell Res 2022 418 2 113266 10.1016/j.yexcr.2022.113266 35752345
Qu Z, Yang KD, Luo BH, Zhang F. CAFs-secreted exosomal cricN4BP2L2 promoted colorectal cancer stemness and chemoresistance by interacting with EIF4A3. Exp Cell Res. 2022;418(2):113266.35752345 10.1016/j.yexcr.2022.113266
72. Hu C Xia R Zhang X Li T Ye Y Li G He R Li Z Lin Q Zheng S Chen R circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis Mol Cancer 2022 21 1 24 10.1186/s12943-022-01501-3 35045883
Hu C, Xia R, Zhang X, Li T, Ye Y, Li G, He R, Li Z, Lin Q, Zheng S, Chen R. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Mol Cancer. 2022;21(1):24.35045883 10.1186/s12943-022-01501-3
73. Zheng S Tian Q Yuan Y Sun S Li T Xia R He R Luo Y Lin Q Fu Z Zhou Y Chen R Hu C Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer J Exp Clin Cancer Res 2023 42 1 324 10.1186/s13046-023-02854-3 38012734
Zheng S, Tian Q, Yuan Y, Sun S, Li T, Xia R, He R, Luo Y, Lin Q, Fu Z, Zhou Y, Chen R, Hu C. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. J Exp Clin Cancer Res. 2023;42(1):324.38012734 10.1186/s13046-023-02854-3
74. Lin S Zhu B Exosome-transmitted FOSL1 from cancer-associated fibroblasts drives colorectal cancer stemness and chemo-resistance through transcriptionally activating ITGB4 Mol Cell Biochem 2024 479 3 665 77 10.1007/s11010-023-04737-9 37160555
Lin S, Zhu B. Exosome-transmitted FOSL1 from cancer-associated fibroblasts drives colorectal cancer stemness and chemo-resistance through transcriptionally activating ITGB4. Mol Cell Biochem. 2024;479(3):665–77.37160555 10.1007/s11010-023-04737-9
75. Claesson-Welsh L Welsh M VEGFA and tumour angiogenesis J Intern Med 2013 273 2 114 27 10.1111/joim.12019 23216836
Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114–27.23216836 10.1111/joim.12019
76. Shi Y Zhu H Jiang H Yue H Yuan F Wang F Cancer-associated fibroblasts-derived exosomes from chemoresistant patients regulate cisplatin resistance and angiogenesis by delivering VEGFA in colorectal cancer Anticancer Drugs 2023 34 3 422 30 36730310
Shi Y, Zhu H, Jiang H, Yue H, Yuan F, Wang F. Cancer-associated fibroblasts-derived exosomes from chemoresistant patients regulate cisplatin resistance and angiogenesis by delivering VEGFA in colorectal cancer. Anticancer Drugs. 2023;34(3):422–30.36730310
77. Allen GM Lim WA Rethinking cancer targeting strategies in the era of smart cell therapeutics Nat Rev Cancer 2022 22 12 693 702 10.1038/s41568-022-00505-x 36175644
Allen GM, Lim WA. Rethinking cancer targeting strategies in the era of smart cell therapeutics. Nat Rev Cancer. 2022;22(12):693–702.36175644 10.1038/s41568-022-00505-x
78. Huang A Garraway LA Ashworth A Weber B Synthetic lethality as an engine for cancer drug target discovery Nat Rev Drug Discov 2020 19 1 23 38 10.1038/s41573-019-0046-z 31712683
Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov. 2020;19(1):23–38.31712683 10.1038/s41573-019-0046-z
79. Aldea M Andre F Marabelle A Dogan S Barlesi F Soria JC Overcoming resistance to Tumor-targeted and Immune-targeted therapies Cancer Discov 2021 11 4 874 99 10.1158/2159-8290.CD-20-1638 33811122
Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC. Overcoming resistance to Tumor-targeted and Immune-targeted therapies. Cancer Discov. 2021;11(4):874–99.33811122 10.1158/2159-8290.CD-20-1638
80. Lim ZF Ma PC Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy J Hematol Oncol 2019 12 1 134 10.1186/s13045-019-0818-2 31815659
Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134.31815659 10.1186/s13045-019-0818-2
81. Nilsson MB Yang Y Heeke S Patel SA Poteete A Udagawa H Elamin YY Moran CA Kashima Y Arumugam T Yu X Ren X Diao L Shen L Wang Q Zhang M Robichaux JP Shi C Pfeil AN Tran H Gibbons DL Bock J Wang J Minna JD Kobayashi SS Le X Heymach JV CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance Cancer Cell 2023 41 2 340 55 10.1016/j.ccell.2023.01.007 36787696
Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023;41(2):340–55. e6.36787696 10.1016/j.ccell.2023.01.007
82. Fiori ME Di Franco S Villanova L Bianca P Stassi G De Maria R Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance Mol Cancer 2019 18 1 70 10.1186/s12943-019-0994-2 30927908
Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70.30927908 10.1186/s12943-019-0994-2
83. Eun JW Yoon JH Ahn HR Kim S Kim YB Lim SB Park W Kang TW Baek GO Yoon MG Son JA Weon JH Kim SS Cho HJ Cheong JY Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib Cancer Commun (Lond) 2023 43 4 455 79 10.1002/cac2.12414 36919193
Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB, Park W, Kang TW, Baek GO, Yoon MG, Son JA, Weon JH, Kim SS, Cho HJ, Cheong JY. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (Lond). 2023;43(4):455–79.36919193 10.1002/cac2.12414
84. Qin W Wang L Tian H Wu X Xiao C Pan Y Fan M Tai Y Liu W Zhang Q Yang Y CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib Mol Carcinog 2022 61 8 764 75 10.1002/mc.23416 35638711
Qin W, Wang L, Tian H, Wu X, Xiao C, Pan Y, Fan M, Tai Y, Liu W, Zhang Q, Yang Y. CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib. Mol Carcinog. 2022;61(8):764–75.35638711 10.1002/mc.23416
85. Zhao J Lin E Bai Z Jia Y Wang B Dai Y Zhuo W Zeng G Liu X Cai C Li P Zou B Li J Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1 BMC Cancer 2023 23 1 1198 10.1186/s12885-023-11613-8 38057830
Zhao J, Lin E, Bai Z, Jia Y, Wang B, Dai Y, Zhuo W, Zeng G, Liu X, Cai C, Li P, Zou B, Li J. Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1. BMC Cancer. 2023;23(1):1198.38057830 10.1186/s12885-023-11613-8
86. Zhang Y Pan Q Shao Z Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib Hum Cell 2023 36 1 296 311 10.1007/s13577-022-00800-7 36424471
Zhang Y, Pan Q, Shao Z. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib. Hum Cell. 2023;36(1):296–311.36424471 10.1007/s13577-022-00800-7
87. Gao Y Li X Zeng C Liu C Hao Q Li W Zhang K Zhang W Wang S Zhao H Fan D Li M Zhang Y Zhang W Zhang C CD63(+) Cancer-Associated fibroblasts Confer tamoxifen resistance to breast Cancer cells through Exosomal miR-22 Adv Sci (Weinh) 2020 7 21 2002518 10.1002/advs.202002518 33173749
Gao Y, Li X, Zeng C, Liu C, Hao Q, Li W, Zhang K, Zhang W, Wang S, Zhao H, Fan D, Li M, Zhang Y, Zhang W, Zhang C. CD63(+) Cancer-Associated fibroblasts Confer tamoxifen resistance to breast Cancer cells through Exosomal miR-22. Adv Sci (Weinh). 2020;7(21):2002518.33173749 10.1002/advs.202002518
88. McLaughlin M Patin EC Pedersen M Wilkins A Dillon MT Melcher AA Harrington KJ Inflammatory microenvironment remodelling by tumour cells after radiotherapy Nat Rev Cancer 2020 20 4 203 17 10.1038/s41568-020-0246-1 32161398
McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, Harrington KJ. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020;20(4):203–17.32161398 10.1038/s41568-020-0246-1
89. Allen C Her S Jaffray DA Radiotherapy for Cancer: Present and Future Adv Drug Deliv Rev 2017 109 1 2 10.1016/j.addr.2017.01.004 28189183
Allen C, Her S, Jaffray DA. Radiotherapy for Cancer: Present and Future. Adv Drug Deliv Rev. 2017;109:1–2.28189183 10.1016/j.addr.2017.01.004
90. Chandra RA Keane FK Voncken FEM Thomas CR Jr Contemporary radiotherapy: present and future Lancet 2021 398 10295 171 84 10.1016/S0140-6736(21)00233-6 34166607
Chandra RA, Keane FK, Voncken FEM, Thomas CR Jr. Contemporary radiotherapy: present and future. Lancet. 2021;398(10295):171–84.34166607 10.1016/S0140-6736(21)00233-6
91. Kim TW Fisetin, an anti-inflammatory Agent, overcomes Radioresistance by activating the PERK-ATF4-CHOP Axis in Liver Cancer Int J Mol Sci 2023 24 10 9076 10.3390/ijms24109076 37240422
Kim TW. Fisetin, an anti-inflammatory Agent, overcomes Radioresistance by activating the PERK-ATF4-CHOP Axis in Liver Cancer. Int J Mol Sci. 2023;24(10):9076.37240422 10.3390/ijms24109076
92. Barker HE Paget JT Khan AA Harrington KJ The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence Nat Rev Cancer 2015 15 7 409 25 10.1038/nrc3958 26105538
Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–25.26105538 10.1038/nrc3958
93. Peng J Yin X Yun W Meng X Huang Z Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance Cancer Lett 2023 559 216108 10.1016/j.canlet.2023.216108 36863506
Peng J, Yin X, Yun W, Meng X, Huang Z. Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance. Cancer Lett. 2023;559:216108.36863506 10.1016/j.canlet.2023.216108
94. Gao LR Zhang J Huang N Deng W Ni W Xiao Z Liu M Tumor-derived exosomal mir-143-3p induces macrophage M2 polarization to cause Radiation Resistance in locally advanced esophageal squamous cell carcinoma Int J Mol Sci 2024 25 11 6082 10.3390/ijms25116082 38892269
Gao LR, Zhang J, Huang N, Deng W, Ni W, Xiao Z, Liu M. Tumor-derived exosomal mir-143-3p induces macrophage M2 polarization to cause Radiation Resistance in locally advanced esophageal squamous cell carcinoma. Int J Mol Sci. 2024;25(11):6082.38892269 10.3390/ijms25116082
95. Liu L Zhang Z Zhou L Hu L Yin C Qing D Huang S Cai X Chen Y Cancer associated fibroblasts-derived exosomes contribute to radioresistance through promoting colorectal cancer stem cells phenotype Exp Cell Res 2020 391 2 111956 10.1016/j.yexcr.2020.111956 32169425
Liu L, Zhang Z, Zhou L, Hu L, Yin C, Qing D, Huang S, Cai X, Chen Y. Cancer associated fibroblasts-derived exosomes contribute to radioresistance through promoting colorectal cancer stem cells phenotype. Exp Cell Res. 2020;391(2):111956.32169425 10.1016/j.yexcr.2020.111956
96. Chen X Liu Y Zhang Q Liu B Cheng Y Zhang Y Sun Y Liu J Exosomal mir-590-3p derived from cancer-associated fibroblasts confers radioresistance in colorectal cancer Mol Ther Nucleic Acids 2021 24 113 26 10.1016/j.omtn.2020.11.003 33738143
Chen X, Liu Y, Zhang Q, Liu B, Cheng Y, Zhang Y, Sun Y, Liu J. Exosomal mir-590-3p derived from cancer-associated fibroblasts confers radioresistance in colorectal cancer. Mol Ther Nucleic Acids. 2021;24:113–26.33738143 10.1016/j.omtn.2020.11.003
97. Chen X Liu J Zhang Q Liu B Cheng Y Zhang Y Sun Y Ge H Liu Y Exosome-mediated transfer of mir-93-5p from cancer-associated fibroblasts confer radioresistance in colorectal cancer cells by downregulating FOXA1 and upregulating TGFB3 J Exp Clin Cancer Res 2020 39 1 65 10.1186/s13046-019-1507-2 32293494
Chen X, Liu J, Zhang Q, Liu B, Cheng Y, Zhang Y, Sun Y, Ge H, Liu Y. Exosome-mediated transfer of mir-93-5p from cancer-associated fibroblasts confer radioresistance in colorectal cancer cells by downregulating FOXA1 and upregulating TGFB3. J Exp Clin Cancer Res. 2020;39(1):65.32293494 10.1186/s13046-019-1507-2
98. Yao F Shi W Fang F Lv MY Xu M Wu SY Huang CL Exosomal miR-196a-5p enhances radioresistance in lung cancer cells by downregulating NFKBIA Kaohsiung J Med Sci 2023 39 6 554 64 10.1002/kjm2.12673 36912495
Yao F, Shi W, Fang F, Lv MY, Xu M, Wu SY, Huang CL. Exosomal miR-196a-5p enhances radioresistance in lung cancer cells by downregulating NFKBIA. Kaohsiung J Med Sci. 2023;39(6):554–64.36912495 10.1002/kjm2.12673
99. Zhou X, Tong Y, Yu C, Pu J, Zhu W, Zhou Y, Wang Y, Xiong Y, Sun X. FAP positive cancer-associated fibroblasts promote tumor progression and radioresistance in esophageal squamous cell carcinoma by transferring exosomal lncRNA AFAP1-AS1. Mol Carcinog. 2024.
100. Kennedy LB Salama AKS A review of cancer immunotherapy toxicity CA Cancer J Clin 2020 70 2 86 104 10.3322/caac.21596 31944278
Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104.31944278 10.3322/caac.21596
101. Riley RS June CH Langer R Mitchell MJ Delivery technologies for cancer immunotherapy Nat Rev Drug Discov 2019 18 3 175 96 10.1038/s41573-018-0006-z 30622344
Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–96.30622344 10.1038/s41573-018-0006-z
102. Schoenfeld AJ Hellmann MD Acquired Resistance to Immune Checkpoint inhibitors Cancer Cell 2020 37 4 443 55 10.1016/j.ccell.2020.03.017 32289269
Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint inhibitors. Cancer Cell. 2020;37(4):443–55.32289269 10.1016/j.ccell.2020.03.017
103. O’Donnell JS Teng MWL Smyth MJ Cancer immunoediting and resistance to T cell-based immunotherapy Nat Rev Clin Oncol 2019 16 3 151 67 10.1038/s41571-018-0142-8 30523282
O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–67.30523282 10.1038/s41571-018-0142-8
104. Rui R Zhou L He S Cancer immunotherapies: advances and bottlenecks Front Immunol 2023 14 1212476 10.3389/fimmu.2023.1212476 37691932
Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476.37691932 10.3389/fimmu.2023.1212476
105. Akiyama T Yasuda T Uchihara T Yasuda-Yoshihara N Tan BJY Yonemura A Semba T Yamasaki J Komohara Y Ohnishi K Wei F Fu L Zhang J Kitamura F Yamashita K Eto K Iwagami S Tsukamoto H Umemoto T Masuda M Nagano O Satou Y Saya H Tan P Baba H Ishimoto T Stromal reprogramming through dual PDGFRα/β blockade boosts the efficacy of Anti-PD-1 immunotherapy in fibrotic tumors Cancer Res 2023 83 5 753 70 10.1158/0008-5472.CAN-22-1890 36543251
Akiyama T, Yasuda T, Uchihara T, Yasuda-Yoshihara N, Tan BJY, Yonemura A, Semba T, Yamasaki J, Komohara Y, Ohnishi K, Wei F, Fu L, Zhang J, Kitamura F, Yamashita K, Eto K, Iwagami S, Tsukamoto H, Umemoto T, Masuda M, Nagano O, Satou Y, Saya H, Tan P, Baba H, Ishimoto T. Stromal reprogramming through dual PDGFRα/β blockade boosts the efficacy of Anti-PD-1 immunotherapy in fibrotic tumors. Cancer Res. 2023;83(5):753–70.36543251 10.1158/0008-5472.CAN-22-1890
106. Feins S Kong W Williams EF Milone MC Fraietta JA An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer Am J Hematol 2019 94 S1 S3 9 10.1002/ajh.25418 30680780
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–9.30680780 10.1002/ajh.25418
107. Saxena M van der Burg SH Melief CJM Bhardwaj N Therapeutic cancer vaccines Nat Rev Cancer 2021 21 6 360 78 10.1038/s41568-021-00346-0 33907315
Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–78.33907315 10.1038/s41568-021-00346-0
108. Restifo NP Dudley ME Rosenberg SA Adoptive immunotherapy for cancer: harnessing the T cell response Nat Rev Immunol 2012 12 4 269 81 10.1038/nri3191 22437939
Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269–81.22437939 10.1038/nri3191
109. Bashash D Zandi Z Kashani B Pourbagheri-Sigaroodi A Salari S Ghaffari SH Resistance to immunotherapy in human malignancies: mechanisms, research progresses, challenges, and opportunities J Cell Physiol 2022 237 1 346 72 10.1002/jcp.30575 34498289
Bashash D, Zandi Z, Kashani B, Pourbagheri-Sigaroodi A, Salari S, Ghaffari SH. Resistance to immunotherapy in human malignancies: mechanisms, research progresses, challenges, and opportunities. J Cell Physiol. 2022;237(1):346–72.34498289 10.1002/jcp.30575
110. Kieffer Y Hocine HR Gentric G Pelon F Bernard C Bourachot B Lameiras S Albergante L Bonneau C Guyard A Tarte K Zinovyev A Baulande S Zalcman G Vincent-Salomon A Mechta-Grigoriou, single-cell analysis reveals fibroblast clusters linked to Immunotherapy Resistance in Cancer Cancer Discov 2020 10 9 1330 51 10.1158/2159-8290.CD-19-1384 32434947
Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, Lameiras S, Albergante L, Bonneau C, Guyard A, Tarte K, Zinovyev A, Baulande S, Zalcman G, Vincent-Salomon A. Mechta-Grigoriou, single-cell analysis reveals fibroblast clusters linked to Immunotherapy Resistance in Cancer. Cancer Discov. 2020;10(9):1330–51.32434947 10.1158/2159-8290.CD-19-1384
111. Jenkins L Jungwirth U Avgustinova A Iravani M Mills A Haider S Harper J Isacke CM Cancer-Associated fibroblasts suppress CD8 + T-cell infiltration and Confer Resistance to Immune-Checkpoint Blockade Cancer Res 2022 82 16 2904 17 10.1158/0008-5472.CAN-21-4141 35749591
Jenkins L, Jungwirth U, Avgustinova A, Iravani M, Mills A, Haider S, Harper J, Isacke CM. Cancer-Associated fibroblasts suppress CD8 + T-cell infiltration and Confer Resistance to Immune-Checkpoint Blockade. Cancer Res. 2022;82(16):2904–17.35749591 10.1158/0008-5472.CAN-21-4141
112. Zhu GQ Tang Z Huang R Qu WF Fang Y Yang R Tao CY Gao J Wu XL Sun HX Zhou YF Song SS Ding ZB Dai Z Zhou J Ye D Wu DJ Liu WR Fan J Shi YH CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor Cell Discov 2023 9 1 25 10.1038/s41421-023-00529-z 36878933
Zhu GQ, Tang Z, Huang R, Qu WF, Fang Y, Yang R, Tao CY, Gao J, Wu XL, Sun HX, Zhou YF, Song SS, Ding ZB, Dai Z, Zhou J, Ye D, Wu DJ, Liu WR, Fan J, Shi YH. CD36(+) cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023;9(1):25.36878933 10.1038/s41421-023-00529-z
113. Dou D, Ren X, Han M, Xu X, Ge X, Gu Y, Wang X. Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway. Front Immunol. 2020;11:2026.
114. Ziani L Buart S Chouaib S Thiery J Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity Oncoimmunology 2021 10 1 1950953 10.1080/2162402X.2021.1950953 34367731
Ziani L, Buart S, Chouaib S, Thiery J. Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity. Oncoimmunology. 2021;10(1):1950953.34367731 10.1080/2162402X.2021.1950953
115. Yang K Zhang J Bao C Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis BMC Cancer 2021 21 1 933 10.1186/s12885-021-08669-9 34412616
Yang K, Zhang J, Bao C. Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis. BMC Cancer. 2021;21(1):933.34412616 10.1186/s12885-021-08669-9
116. Yu S Yang R Xu T Li X Wu S Zhang J Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer Gynecol Oncol 2022 167 2 342 53 10.1016/j.ygyno.2022.09.003 36114029
Yu S, Yang R, Xu T, Li X, Wu S, Zhang J. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer. Gynecol Oncol. 2022;167(2):342–53.36114029 10.1016/j.ygyno.2022.09.003
117. Feng R Li Z Ge G Wang C Jia Y Ouyang J Cancer-associated fibroblast-derived Extracellular vesicles mediate Immune escape of bladder Cancer via PD-L1/PD-1 expression Endocr Metab Immune Disord Drug Targets 2023 23 11 1410 20 10.2174/1871530323666230228124125 36852791
Feng R, Li Z, Ge G, Wang C, Jia Y, Ouyang J. Cancer-associated fibroblast-derived Extracellular vesicles mediate Immune escape of bladder Cancer via PD-L1/PD-1 expression. Endocr Metab Immune Disord Drug Targets. 2023;23(11):1410–20.36852791 10.2174/1871530323666230228124125
118. Ma S Zhou M Xu Y Gu X Zou M Abudushalamu G Yao Y Fan X Wu G Clinical application and detection techniques of liquid biopsy in gastric cancer Mol Cancer 2023 22 1 7 10.1186/s12943-023-01715-z 36627698
Ma S, Zhou M, Xu Y, Gu X, Zou M, Abudushalamu G, Yao Y, Fan X, Wu G. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol Cancer. 2023;22(1):7.36627698 10.1186/s12943-023-01715-z
119. Yu D Li Y Wang M Gu J Xu W Cai H Fang X Zhang X Exosomes as a new frontier of cancer liquid biopsy Mol Cancer 2022 21 1 56 10.1186/s12943-022-01509-9 35180868
Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, Fang X, Zhang X. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022;21(1):56.35180868 10.1186/s12943-022-01509-9
120. Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S, Mark MT, Steiner L, Benito-Martin A, Lucotti S, Di Giannatale A, Offer K, Nakajima M, Williams C, Nogues L, Pelissier Vatter FA, Hashimoto A, Davies AE, Freitas D, Kenific CM, Ararso Y, Buehring W, Lauritzen P, Ogitani Y, Sugiura K, Takahashi N, Aleckovic M, Bailey KA, Jolissant JS, Wang H, Harris A, Schaeffer LM, Garcia-Santos G, Posner Z, Balachandran VP, Khakoo Y, Raju GP, Scherz A, Sagi I, Scherz-Shouval R, Yarden Y, Oren M, Malladi M, Petriccione M, De Braganca KC, Donzelli M, Fischer C, Vitolano S, Wright GP, Ganshaw L, Marrano M, Ahmed A, DeStefano J, Danzer E, Roehrl MHA, Lacayo NJ, Vincent TC, Weiser MR, Brady MS, Meyers PA, Wexler LH, Ambati SR, Chou AJ, Slotkin EK, Modak S, Roberts SS, Basu EM, Diolaiti D, Krantz BA, Cardoso F, Simpson AL, Berger M, Rudin CM, Simeone DM, Jain M, Ghajar CM, Batra SK, Stanger BZ, Bui J, Brown KA, Rajasekhar VK, Healey JH, de Sousa M, Kramer K, Sheth S, Baisch J, Pascual V, Heaton TE, La Quaglia MP, Pisapia DJ, Schwartz R, Zhang H, Liu Y, Shukla A, Blavier L, DeClerck YA, LaBarge M, Bissell MJ, Caffrey TC, Grandgenett PM, Hollingsworth MA, Bromberg J, Costa-Silva B, Peinado H, Kang Y, Garcia BA. E.M. O’Reilly, D. Kelsen, T.M. Trippett, D.R. Jones, I.R. Matei, W.R. Jarnagin, D. Lyden, Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell. 182(4):2020:1044–1061 e18.
121. McKiernan J Donovan MJ O’Neill V Bentink S Noerholm M Belzer S Skog J Kattan MW Partin A Andriole G Brown G Wei JT Thompson IM Jr Carroll P A novel urine exosome gene expression assay to Predict High-grade prostate Cancer at initial biopsy JAMA Oncol 2016 2 7 882 9 10.1001/jamaoncol.2016.0097 27032035
McKiernan J, Donovan MJ, O’Neill V, Bentink S, Noerholm M, Belzer S, Skog J, Kattan MW, Partin A, Andriole G, Brown G, Wei JT, Thompson IM Jr., Carroll P. A novel urine exosome gene expression assay to Predict High-grade prostate Cancer at initial biopsy. JAMA Oncol. 2016;2(7):882–9.27032035 10.1001/jamaoncol.2016.0097
122. Margolis E Brown G Partin A Carter B McKiernan J Tutrone R Torkler P Fischer C Tadigotla V Noerholm M Donovan MJ Skog J Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) prostate intelliscore test in three independent prospective studies Prostate Cancer Prostatic Dis 2022 25 2 296 301 10.1038/s41391-021-00456-8 34593984
Margolis E, Brown G, Partin A, Carter B, McKiernan J, Tutrone R, Torkler P, Fischer C, Tadigotla V, Noerholm M, Donovan MJ, Skog J. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) prostate intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 2022;25(2):296–301.34593984 10.1038/s41391-021-00456-8
123. Woo J Santasusagna S Banks J Pastor-Lopez S Yadav K Carceles-Cordon M Dominguez-Andres A Den RB Languino LR Pippa R Lallas CD Lu-Yao G Kelly WK Knudsen KE Rodriguez-Bravo V Tewari AK Prats JM Leiby BE Gomella LG Domingo-Domenech, urine extracellular vesicle GATA2 mRNA discriminates Biopsy result in men with suspicion of prostate Cancer J Urol 2020 204 4 691 700 10.1097/JU.0000000000001066 32250729
Woo J, Santasusagna S, Banks J, Pastor-Lopez S, Yadav K, Carceles-Cordon M, Dominguez-Andres A, Den RB, Languino LR, Pippa R, Lallas CD, Lu-Yao G, Kelly WK, Knudsen KE, Rodriguez-Bravo V, Tewari AK, Prats JM, Leiby BE, Gomella LG. Domingo-Domenech, urine extracellular vesicle GATA2 mRNA discriminates Biopsy result in men with suspicion of prostate Cancer. J Urol. 2020;204(4):691–700.32250729 10.1097/JU.0000000000001066
124. Qin X Guo H Wang X Zhu X Yan M Wang X Xu Q Shi J Lu E Chen W Zhang J Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5 Genome Biol 2019 20 1 12 10.1186/s13059-018-1604-0 30642385
Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, Xu Q, Shi J, Lu E, Chen W, Zhang J. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20(1):12.30642385 10.1186/s13059-018-1604-0
125. Wang X Qin X Yan M Shi J Xu Q Li Z Yang W Zhang J Chen W Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression J Exp Clin Cancer Res 2019 38 1 151 10.1186/s13046-019-1144-9 30961650
Wang X, Qin X, Yan M, Shi J, Xu Q, Li Z, Yang W, Zhang J, Chen W. Loss of exosomal miR-3188 in cancer-associated fibroblasts contributes to HNC progression. J Exp Clin Cancer Res. 2019;38(1):151.30961650 10.1186/s13046-019-1144-9
126. Yugawa K Yoshizumi T Mano Y Itoh S Harada N Ikegami T Kohashi K Oda Y Mori M Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p Eur J Surg Oncol 2021 47 2 384 93 10.1016/j.ejso.2020.08.002 32883551
Yugawa K, Yoshizumi T, Mano Y, Itoh S, Harada N, Ikegami T, Kohashi K, Oda Y, Mori M. Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. Eur J Surg Oncol. 2021;47(2):384–93.32883551 10.1016/j.ejso.2020.08.002
127. Del Re M Marconcini R Pasquini G Rofi E Vivaldi C Bloise F Restante G Arrigoni E Caparello C Bianco MG Crucitta S Petrini I Vasile E Falcone A Danesi R PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC Br J Cancer 2018 118 6 820 4 10.1038/bjc.2018.9 29509748
Del Re M, Marconcini R, Pasquini G, Rofi E, Vivaldi C, Bloise F, Restante G, Arrigoni E, Caparello C, Bianco MG, Crucitta S, Petrini I, Vasile E, Falcone A, Danesi R. PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. Br J Cancer. 2018;118(6):820–4.29509748 10.1038/bjc.2018.9
128. Toshida K Itoh S Harada N Morinaga A Yugawa K Tomiyama T Kosai-Fujimoto Y Tomino T Kurihara T Nagao Y Morita K Oda Y Yoshizumi T Cancer-associated fibroblasts promote tumor cell growth via mir-493-5p in intrahepatic cholangiocarcinoma Cancer Sci 2023 114 3 937 47 10.1111/cas.15644 36369960
Toshida K, Itoh S, Harada N, Morinaga A, Yugawa K, Tomiyama T, Kosai-Fujimoto Y, Tomino T, Kurihara T, Nagao Y, Morita K, Oda Y, Yoshizumi T. Cancer-associated fibroblasts promote tumor cell growth via mir-493-5p in intrahepatic cholangiocarcinoma. Cancer Sci. 2023;114(3):937–47.36369960 10.1111/cas.15644
129. Leca J Martinez S Lac S Nigri J Secq V Rubis M Bressy C Serge A Lavaut MN Dusetti N Loncle C Roques J Pietrasz D Bousquet C Garcia S Granjeaud S Ouaissi M Bachet JB Brun C Iovanna JL Zimmermann P Vasseur S Tomasini R Cancer-associated fibroblast-derived annexin A6 + extracellular vesicles support pancreatic cancer aggressiveness J Clin Invest 2016 126 11 4140 56 10.1172/JCI87734 27701147
Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Serge A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouaissi M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R. Cancer-associated fibroblast-derived annexin A6 + extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest. 2016;126(11):4140–56.27701147 10.1172/JCI87734
130. Peng Z Tong Z Ren Z Ye M Hu K Cancer-associated fibroblasts and its derived exosomes: a new perspective for reshaping the tumor microenvironment Mol Med 2023 29 1 66 10.1186/s10020-023-00665-y 37217855
Peng Z, Tong Z, Ren Z, Ye M, Hu K. Cancer-associated fibroblasts and its derived exosomes: a new perspective for reshaping the tumor microenvironment. Mol Med. 2023;29(1):66.37217855 10.1186/s10020-023-00665-y
131. Zhang M Hu S Liu L Dang P Liu Y Sun Z Qiao B Wang C Engineered exosomes from different sources for cancer-targeted therapy Signal Transduct Target Ther 2023 8 1 124 10.1038/s41392-023-01382-y 36922504
Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, Qiao B, Wang C. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8(1):124.36922504 10.1038/s41392-023-01382-y
132. Zuo R Liu M Wang Y Li J Wang W Wu J Sun C Li B Wang Z Lan W Zhang C Shi C Zhou Y BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/beta-catenin signaling Stem Cell Res Ther 2019 10 1 30 10.1186/s13287-018-1121-9 30646958
Zuo R, Liu M, Wang Y, Li J, Wang W, Wu J, Sun C, Li B, Wang Z, Lan W, Zhang C, Shi C, Zhou Y. BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/beta-catenin signaling. Stem Cell Res Ther. 2019;10(1):30.30646958 10.1186/s13287-018-1121-9
133. Lin Z Wu Y Xu Y Li G Li Z Liu T Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential Mol Cancer 2022 21 1 179 10.1186/s12943-022-01650-5 36100944
Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential. Mol Cancer. 2022;21(1):179.36100944 10.1186/s12943-022-01650-5
134. Ru Q Chen L Xu G Wu Y Exosomes in the pathogenesis and treatment of cancer-related cachexia J Transl Med 2024 22 1 408 10.1186/s12967-024-05201-y 38689293
Ru Q, Chen L, Xu G, Wu Y. Exosomes in the pathogenesis and treatment of cancer-related cachexia. J Transl Med. 2024;22(1):408.38689293 10.1186/s12967-024-05201-y
135. Waise S Parker R Rose-Zerilli MJJ Layfield DM Wood O West J Ottensmeier CH Thomas GJ Hanley CJ An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing Sci Rep 2019 9 1 9580 10.1038/s41598-019-45842-4 31270426
Waise S, Parker R, Rose-Zerilli MJJ, Layfield DM, Wood O, West J, Ottensmeier CH, Thomas GJ, Hanley CJ. An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing. Sci Rep. 2019;9(1):9580.31270426 10.1038/s41598-019-45842-4
136. Zhang H Song Q Shang K Li Y Jiang L Yang L Tspan protein family: focusing on the occurrence, progression, and treatment of cancer Cell Death Discov 2024 10 1 187 10.1038/s41420-024-01961-0 38649381
Zhang H, Song Q, Shang K, Li Y, Jiang L, Yang L. Tspan protein family: focusing on the occurrence, progression, and treatment of cancer. Cell Death Discov. 2024;10(1):187.38649381 10.1038/s41420-024-01961-0
137. Garcia-Mayea Y Mir C Carballo L Sanchez-Garcia A Bataller M ME LL TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance Biochim Biophys Acta Rev Cancer 2022 1877 1 188674 10.1016/j.bbcan.2021.188674 34979155
Garcia-Mayea Y, Mir C, Carballo L, Sanchez-Garcia A, Bataller M, ME LL. TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance. Biochim Biophys Acta Rev Cancer. 2022;1877(1):188674.34979155 10.1016/j.bbcan.2021.188674
138. Kim JH Lee CH Baek MC Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer Exp Mol Med 2022 54 11 1833 43 10.1038/s12276-022-00898-7 36446847
Kim JH, Lee CH, Baek MC. Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer. Exp Mol Med. 2022;54(11):1833–43.36446847 10.1038/s12276-022-00898-7
139. Catalano M O’Driscoll L Inhibiting extracellular vesicles formation and release: a review of EV inhibitors J Extracell Vesicles 2020 9 1 1703244 10.1080/20013078.2019.1703244 32002167
Catalano M, O’Driscoll L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2020;9(1):1703244.32002167 10.1080/20013078.2019.1703244
